1. Description of Business and Summary
Goodness Growth Holdings,\u00a0Inc. (\u201cGoodness Growth\u201d or the \u201cCompany\u201d) (formerly, Vireo Health International, Inc.) was incorporated under the Alberta Business Corporations Act on November\u00a023, 2004. The Company was previously listed on the Canadian Securities Exchange (the \u201cCSE\u201d) under ticker symbol \u201cVREO\u201d. On June 9, 2021, the Company changed its name to Goodness Growth Holdings, Inc. and its ticker symbol on the CSE to \u201cGDNS.\u201d
Goodness Growth is a cannabis company whose mission is to provide safe access, quality products and value to its customers while supporting its local communities through active participation and restorative justice programs. Goodness Growth operates cannabis cultivation, production, and dispensary facilities in Maryland, Minnesota, and New York, and formerly in Arizona and New Mexico.
While marijuana and CBD-infused products are legal under the laws of several U.S. states (with vastly differing restrictions), the United States Federal Controlled Substances Act classifies all \u201cmarijuana\u201d as a Schedule I drug. Under U.S. federal law, a Schedule I drug or substance has a high potential for abuse, no accepted medical use in the United States, and a lack of safety for the use of the drug under medical supervision. Recently some federal officials have attempted to distinguish between medical cannabis use as necessary, but adult-use as \u201cstill a violation of federal law.\u201d At the present time, the distinction between \u201cmedical marijuana\u201d and \u201cadult-use marijuana\u201d does not exist under U.S. federal law.
On January 31, 2022, the Company entered into an Arrangement Agreement (the \u201cArrangement Agreement\u201d) with Verano Holdings Corp. (\u201cVerano\u201d), pursuant to which Verano was to acquire all of the issued and outstanding shares of Goodness Growth pursuant to a plan of arrangement (the \u201cPlan of Arrangement\u201d) under the Business Corporations Act (British Columbia) (the \u201cArrangement\u201d). Subject to the terms and conditions set forth in the Arrangement Agreement and the Plan of Arrangement, holders of Goodness Growth Shares would receive\u00a00.22652\u00a0of a subordinate voting share of Verano (each a \u201cVerano Subordinate Voting Share\u201d), subject to adjustment as described below (the \u201cExchange Ratio\u201d), for each Subordinate Voting Share held, and\u00a022.652\u00a0Verano Subordinate Voting Shares for each Multiple Voting Share and Super Voting Share held, immediately prior to the effective time of the Arrangement.
On October 13, 2022, Goodness Growth received a notice of purported termination of the Arrangement Agreement (the \u201cNotice\u201d) from Verano. The Notice asserted certain breaches of the Arrangement Agreement, including claims the Company\u2019s public filings and communications with respect to its business and ongoing operations were misleading and that the Company breached its representations to Verano under the Arrangement Agreement. Verano also claimed, as a result of such breaches, it is entitled to payment of the $14,875,000\u00a0termination fee and its transaction expenses. Goodness Growth denies all of Verano\u2019s allegations and affirmatively asserts that it has complied with its obligations under the Arrangement Agreement, and with its disclosure obligations under US and Canadian law, in all material respects at all times. The Company believes that Verano has no factual or legal basis to justify or support its purported grounds for termination of the Arrangement Agreement.
On October 21, 2022, Goodness Growth commenced an action in the Supreme Court of British Columbia against Verano after Verano repudiated the Arrangement Agreement. The Company is seeking damages, costs and interest, based on Verano's breach of contract and of its duty of good faith and honest performance.
On November 14, 2022, Verano filed counterclaims against the Company for the termination fee and transaction expenses described above.
On July 31, 2023, the Company filed a requisition for adjournment of its application filed July 14, 2023, and set for hearing on July 31, 2023 to compel Verano\u2019s compliance with document production.
Throughout 2023, the Company served\u00a04\u00a0lists of documents, reviewed document production from Verano, and prepared for examinations for discovery. \u00a0The Company also prepared materials in anticipation of seeking summary determination of its claim.
Due to uncertainties inherent in litigation, it is not possible for Goodness Growth to predict the timing or final outcome of the legal proceedings against Verano or to determine the amount of damages, if any, that may be awarded.
The termination of the Arrangement Agreement gives rise to substantial doubt about the Company\u2019s ability to continue as a going concern. Company management is working with the Company\u2019s lenders, counsel, and other applicable parties to implement a plan to effectively mitigate the conditions giving rise to substantial doubt. Elements of this plan may include, but are not limited to, asset sales, debt restructuring, and capital raises. The accompanying consolidated financial statements have been prepared on a going concern basis, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. However, the Company\u2019s continuance as a going concern is dependent on its future profitability and implementation of the aforementioned plan. The Company may not be successful in these efforts.
"}]},{"name":"rpt:f-251","factDimensions":{"xbrl:concept":"gdnsf:ExchangeRatioOfSharesReceivable","xbrl:period":"2022-02-01T00:00:00","xbrl:entity":"cik:0001771706","us-gaap:StatementClassOfStockAxis":"gdnsf:SubordinateVotingSharesMember","us-gaap:TypeOfArrangementAxis":"gdnsf:ArrangementAgreementWithVeranoHoldingsCorpMember"},"factValues":[{"value":"0.22652","decimals":5}]},{"name":"rpt:f-252","factDimensions":{"xbrl:concept":"gdnsf:ExchangeRatioOfSharesReceivable","xbrl:period":"2022-02-01T00:00:00","xbrl:entity":"cik:0001771706","us-gaap:StatementClassOfStockAxis":"gdnsf:MultipleVotingSharesMember","us-gaap:TypeOfArrangementAxis":"gdnsf:ArrangementAgreementWithVeranoHoldingsCorpMember"},"factValues":[{"value":"22.652","decimals":3}]},{"name":"rpt:f-253","factDimensions":{"xbrl:concept":"us-gaap:LossContingencyDamagesSoughtValue","xbrl:period":"2022-10-13T00:00:00/2022-10-14T00:00:00","xbrl:entity":"cik:0001771706","xbrl:unit":"iso4217:USD","us-gaap:TypeOfArrangementAxis":"gdnsf:ArrangementAgreementWithVeranoHoldingsCorpMember"},"factValues":[{"value":"14875000","decimals":0}]},{"name":"rpt:f-254","factDimensions":{"xbrl:concept":"gdnsf:LossContingencyListOfDocumentsServedForExaminationNumber","xbrl:period":"2024-01-01T00:00:00/2024-04-01T00:00:00","xbrl:entity":"cik:0001771706","xbrl:unit":"gdnsf:item","us-gaap:TypeOfArrangementAxis":"gdnsf:ArrangementAgreementWithVeranoHoldingsCorpMember"},"factValues":[{"value":"4"}]},{"name":"rpt:f-255","factDimensions":{"xbrl:concept":"us-gaap:SignificantAccountingPoliciesTextBlock","xbrl:period":"2024-01-01T00:00:00/2024-04-01T00:00:00","xbrl:entity":"cik:0001771706"},"factValues":[{"value":"2. Summary of Significant Accounting Policies
Significant Accounting Policies
The Company\u2019s significant accounting policies are described in Note 2 to the Company\u2019s consolidated financial statements included in the Annual Report on Form 10-K for the fiscal year ended December 31, 2023, filed with the United States Securities and Exchange Commission (\u201cSEC\u201d) on April 1, 2024, (the \"Annual Financial Statements\"), as amended on April 29, 2024. There have been no material changes to the Company\u2019s significant accounting policies.
Basis of presentation
The accompanying unaudited condensed consolidated financial statements reflect the accounts of the Company. The information included in these statements should be read in conjunction with the Annual Financial Statements. The unaudited condensed consolidated financial statements were prepared in accordance with generally accepted accounting principles in the United States of America (\u201cU.S. GAAP\u201d) and pursuant to the rules\u00a0and regulations of the SEC. In the opinion of management, the financial data presented includes all adjustments necessary to present fairly the financial position, results of operations and cash flows for the interim periods presented. Results of interim periods should not be considered indicative of the results for the full year. These unaudited interim condensed consolidated financial statements include estimates and assumptions of management that affect the amounts reported in the unaudited condensed consolidated financial statements. Actual results could differ from these estimates.
Basis of consolidation
These unaudited condensed consolidated financial statements include the accounts of the following entities wholly owned, or effectively controlled by the Company during the period ended March 31, 2024:
Name of entity | \u00a0\u00a0\u00a0\u00a0 | Place\u00a0of\u00a0\u00a0incorporation |
Vireo Health, Inc. | \u00a0 | Delaware, USA |
Vireo Health of New York, LLC | \u00a0 | New York, USA |
Minnesota Medical Solutions, LLC | \u00a0 | Minnesota, USA |
MaryMed, LLC | \u00a0 | Maryland, USA |
Vireo of Charm City, LLC | Maryland, USA | |
Vireo Health of Massachusetts, LLC | \u00a0 | Delaware, USA |
Mayflower Botanicals, Inc. | \u00a0 | Massachusetts, USA |
Resurgent Biosciences, Inc. | \u00a0 | Delaware, USA |
Vireo Health of Puerto Rico, LLC | \u00a0 | Delaware, USA |
Vireo Health de Puerto Rico, Inc. | \u00a0 | Puerto Rico |
XAAS Agro, Inc. | \u00a0 | Puerto Rico |
Vireo Health of Nevada 1, LLC | \u00a0 | Nevada, USA |
Verdant Grove, Inc. | \u00a0 | Massachusetts, USA |
The entities listed are wholly owned or effectively controlled by the Company and have been formed or acquired to support the intended operations of the Company, and all intercompany transactions and balances have been eliminated in the Company's unaudited condensed consolidated financial statements. Red Barn Growers, Inc. and all New Mexico assets and liabilities were divested in June of 2023.
Recently adopted accounting pronouncements
None.
Net loss per share
Basic net loss per share is computed by dividing reported net loss by the weighted average number of common shares outstanding for the reported period. Diluted net loss per share reflects the potential dilution that could occur if securities or other contracts to issue common stock were exercised or converted into common stock of the Company during the reporting period. Diluted net loss per share is computed by dividing net loss by the sum of the weighted average number of common shares and the number of potential dilutive common share equivalents outstanding during the period. Potential dilutive common share equivalents consist of the incremental common shares issuable upon the exercise of vested share options and the incremental shares issuable upon conversion of the convertible notes. Potential dilutive common share equivalents consist of stock options, warrants, and restricted stock units.
In computing diluted earnings per share, common share equivalents are not considered in periods in which a net loss is reported, as the inclusion of the common share equivalents would be anti-dilutive. The Company recorded a net loss for the three month periods ended March 31, 2024, and 2023, presented in these financial statements, and as such there is no difference between the Company\u2019s basic and diluted net loss per share for these periods.
The anti-dilutive shares outstanding for the three month period ending March 31, 2024, and 2023 were as follows:
March\u00a031,\u00a0 | ||||
2024 | \u00a0\u00a0\u00a0\u00a0 | 2023 | ||
Stock options | 29,945,511 | \u00a0 | 28,566,282 | |
Warrants | 19,437,649 | \u00a0 | 3,187,649 | |
RSUs | 2,543,011 | 3,102,765 | ||
Convertible debt | 71,569,927 | \u2014 | ||
Total | 123,496,098 | \u00a0 | 34,856,696 |
Revenue Recognition
The Company\u2019s primary source of revenue is from wholesale of cannabis products to dispensary locations and direct retail sales to eligible customers at the Company-owned dispensaries. Substantially all of the Company\u2019s retail revenue is from the direct sale of cannabis products to adult-use and medical customers.
The following table represents the Company\u2019s disaggregated revenue by source:
Three Months Ended | ||||||
\u00a0\u00a0\u00a0\u00a0 | 2024 | \u00a0\u00a0\u00a0\u00a0 | 2023 | |||
Retail | $ | 19,599,440 | $ | 16,471,799 | ||
Wholesale | \u00a0 | 4,487,875 | \u00a0 | 2,616,624 | ||
Total | $ | 24,087,315 | $ | 19,088,423 |
New accounting pronouncements not yet adopted
ASU 2023-07\u00a0In November 2023, the Financial Accounting Standards Board (\u201cFASB\u201d) issued Accounting Standards Update (\"ASU\") 2023-07,\u00a0Improvements to Reportable Segment Disclosures (Topic 280). This ASU updates reportable segment disclosure requirements by requiring disclosures of significant reportable segment expenses that are regularly provided to the Chief Operating Decision Maker (\u201cCODM\u201d) and included within each reported measure of a segment's profit or loss. This ASU also requires disclosure of the title and position of the individual identified as the CODM and an explanation of how the CODM uses the reported measures of a segment\u2019s profit or loss in assessing segment performance and deciding how to allocate resources. The ASU is effective for annual periods beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024.\u00a0The Company has not adopted the standard for the interim periods presented herein, but will adopt the standard on or before December 31, 2024. This ASU will result in additional required disclosures when adopted, where applicable.
ASU 2023-09\u00a0In December 2023, the FASB issued ASU 2023-09,\u00a0Improvements to Income Tax Disclosures (Topic 740). The ASU requires disaggregated information about a reporting entity\u2019s effective tax rate reconciliation as well as additional information on income taxes paid. The ASU is effective on a prospective basis for annual periods beginning after December 15, 2024. Early adoption is also permitted for annual financial statements that have not yet been issued or made available for issuance. Once adopted, this ASU will result in additional disclosures.
"}]},{"name":"rpt:f-256","factDimensions":{"xbrl:concept":"us-gaap:BasisOfAccountingPolicyPolicyTextBlock","xbrl:period":"2024-01-01T00:00:00/2024-04-01T00:00:00","xbrl:entity":"cik:0001771706"},"factValues":[{"value":"Basis of presentation
The accompanying unaudited condensed consolidated financial statements reflect the accounts of the Company. The information included in these statements should be read in conjunction with the Annual Financial Statements. The unaudited condensed consolidated financial statements were prepared in accordance with generally accepted accounting principles in the United States of America (\u201cU.S. GAAP\u201d) and pursuant to the rules\u00a0and regulations of the SEC. In the opinion of management, the financial data presented includes all adjustments necessary to present fairly the financial position, results of operations and cash flows for the interim periods presented. Results of interim periods should not be considered indicative of the results for the full year. These unaudited interim condensed consolidated financial statements include estimates and assumptions of management that affect the amounts reported in the unaudited condensed consolidated financial statements. Actual results could differ from these estimates.
"}]},{"name":"rpt:f-257","factDimensions":{"xbrl:concept":"us-gaap:ConsolidationPolicyTextBlock","xbrl:period":"2024-01-01T00:00:00/2024-04-01T00:00:00","xbrl:entity":"cik:0001771706"},"factValues":[{"value":"Basis of consolidation
These unaudited condensed consolidated financial statements include the accounts of the following entities wholly owned, or effectively controlled by the Company during the period ended March 31, 2024:
Name of entity | \u00a0\u00a0\u00a0\u00a0 | Place\u00a0of\u00a0\u00a0incorporation |
Vireo Health, Inc. | \u00a0 | Delaware, USA |
Vireo Health of New York, LLC | \u00a0 | New York, USA |
Minnesota Medical Solutions, LLC | \u00a0 | Minnesota, USA |
MaryMed, LLC | \u00a0 | Maryland, USA |
Vireo of Charm City, LLC | Maryland, USA | |
Vireo Health of Massachusetts, LLC | \u00a0 | Delaware, USA |
Mayflower Botanicals, Inc. | \u00a0 | Massachusetts, USA |
Resurgent Biosciences, Inc. | \u00a0 | Delaware, USA |
Vireo Health of Puerto Rico, LLC | \u00a0 | Delaware, USA |
Vireo Health de Puerto Rico, Inc. | \u00a0 | Puerto Rico |
XAAS Agro, Inc. | \u00a0 | Puerto Rico |
Vireo Health of Nevada 1, LLC | \u00a0 | Nevada, USA |
Verdant Grove, Inc. | \u00a0 | Massachusetts, USA |
The entities listed are wholly owned or effectively controlled by the Company and have been formed or acquired to support the intended operations of the Company, and all intercompany transactions and balances have been eliminated in the Company's unaudited condensed consolidated financial statements. Red Barn Growers, Inc. and all New Mexico assets and liabilities were divested in June of 2023.
"}]},{"name":"rpt:f-258","factDimensions":{"xbrl:concept":"us-gaap:ScheduleOfInvestmentsInAndAdvancesToAffiliatesScheduleOfInvestmentsTableTextBlock","xbrl:period":"2024-01-01T00:00:00/2024-04-01T00:00:00","xbrl:entity":"cik:0001771706"},"factValues":[{"value":"Name of entity | \u00a0\u00a0\u00a0\u00a0 | Place\u00a0of\u00a0\u00a0incorporation |
Vireo Health, Inc. | \u00a0 | Delaware, USA |
Vireo Health of New York, LLC | \u00a0 | New York, USA |
Minnesota Medical Solutions, LLC | \u00a0 | Minnesota, USA |
MaryMed, LLC | \u00a0 | Maryland, USA |
Vireo of Charm City, LLC | Maryland, USA | |
Vireo Health of Massachusetts, LLC | \u00a0 | Delaware, USA |
Mayflower Botanicals, Inc. | \u00a0 | Massachusetts, USA |
Resurgent Biosciences, Inc. | \u00a0 | Delaware, USA |
Vireo Health of Puerto Rico, LLC | \u00a0 | Delaware, USA |
Vireo Health de Puerto Rico, Inc. | \u00a0 | Puerto Rico |
XAAS Agro, Inc. | \u00a0 | Puerto Rico |
Vireo Health of Nevada 1, LLC | \u00a0 | Nevada, USA |
Verdant Grove, Inc. | \u00a0 | Massachusetts, USA |
Recently adopted accounting pronouncements
None.
New accounting pronouncements not yet adopted
ASU 2023-07\u00a0In November 2023, the Financial Accounting Standards Board (\u201cFASB\u201d) issued Accounting Standards Update (\"ASU\") 2023-07,\u00a0Improvements to Reportable Segment Disclosures (Topic 280). This ASU updates reportable segment disclosure requirements by requiring disclosures of significant reportable segment expenses that are regularly provided to the Chief Operating Decision Maker (\u201cCODM\u201d) and included within each reported measure of a segment's profit or loss. This ASU also requires disclosure of the title and position of the individual identified as the CODM and an explanation of how the CODM uses the reported measures of a segment\u2019s profit or loss in assessing segment performance and deciding how to allocate resources. The ASU is effective for annual periods beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024.\u00a0The Company has not adopted the standard for the interim periods presented herein, but will adopt the standard on or before December 31, 2024. This ASU will result in additional required disclosures when adopted, where applicable.
ASU 2023-09\u00a0In December 2023, the FASB issued ASU 2023-09,\u00a0Improvements to Income Tax Disclosures (Topic 740). The ASU requires disaggregated information about a reporting entity\u2019s effective tax rate reconciliation as well as additional information on income taxes paid. The ASU is effective on a prospective basis for annual periods beginning after December 15, 2024. Early adoption is also permitted for annual financial statements that have not yet been issued or made available for issuance. Once adopted, this ASU will result in additional disclosures.
"}]},{"name":"rpt:f-260","factDimensions":{"xbrl:concept":"us-gaap:EarningsPerSharePolicyTextBlock","xbrl:period":"2024-01-01T00:00:00/2024-04-01T00:00:00","xbrl:entity":"cik:0001771706"},"factValues":[{"value":"Net loss per share
Basic net loss per share is computed by dividing reported net loss by the weighted average number of common shares outstanding for the reported period. Diluted net loss per share reflects the potential dilution that could occur if securities or other contracts to issue common stock were exercised or converted into common stock of the Company during the reporting period. Diluted net loss per share is computed by dividing net loss by the sum of the weighted average number of common shares and the number of potential dilutive common share equivalents outstanding during the period. Potential dilutive common share equivalents consist of the incremental common shares issuable upon the exercise of vested share options and the incremental shares issuable upon conversion of the convertible notes. Potential dilutive common share equivalents consist of stock options, warrants, and restricted stock units.
In computing diluted earnings per share, common share equivalents are not considered in periods in which a net loss is reported, as the inclusion of the common share equivalents would be anti-dilutive. The Company recorded a net loss for the three month periods ended March 31, 2024, and 2023, presented in these financial statements, and as such there is no difference between the Company\u2019s basic and diluted net loss per share for these periods.
The anti-dilutive shares outstanding for the three month period ending March 31, 2024, and 2023 were as follows:
March\u00a031,\u00a0 | ||||
2024 | \u00a0\u00a0\u00a0\u00a0 | 2023 | ||
Stock options | 29,945,511 | \u00a0 | 28,566,282 | |
Warrants | 19,437,649 | \u00a0 | 3,187,649 | |
RSUs | 2,543,011 | 3,102,765 | ||
Convertible debt | 71,569,927 | \u2014 | ||
Total | 123,496,098 | \u00a0 | 34,856,696 |
March\u00a031,\u00a0 | ||||
2024 | \u00a0\u00a0\u00a0\u00a0 | 2023 | ||
Stock options | 29,945,511 | \u00a0 | 28,566,282 | |
Warrants | 19,437,649 | \u00a0 | 3,187,649 | |
RSUs | 2,543,011 | 3,102,765 | ||
Convertible debt | 71,569,927 | \u2014 | ||
Total | 123,496,098 | \u00a0 | 34,856,696 |
Revenue Recognition
The Company\u2019s primary source of revenue is from wholesale of cannabis products to dispensary locations and direct retail sales to eligible customers at the Company-owned dispensaries. Substantially all of the Company\u2019s retail revenue is from the direct sale of cannabis products to adult-use and medical customers.
The following table represents the Company\u2019s disaggregated revenue by source:
Three Months Ended | ||||||
\u00a0\u00a0\u00a0\u00a0 | 2024 | \u00a0\u00a0\u00a0\u00a0 | 2023 | |||
Retail | $ | 19,599,440 | $ | 16,471,799 | ||
Wholesale | \u00a0 | 4,487,875 | \u00a0 | 2,616,624 | ||
Total | $ | 24,087,315 | $ | 19,088,423 |
Three Months Ended | ||||||
\u00a0\u00a0\u00a0\u00a0 | 2024 | \u00a0\u00a0\u00a0\u00a0 | 2023 | |||
Retail | $ | 19,599,440 | $ | 16,471,799 | ||
Wholesale | \u00a0 | 4,487,875 | \u00a0 | 2,616,624 | ||
Total | $ | 24,087,315 | $ | 19,088,423 |
3. Business Combinations and Dispositions
Assets Held for Sale
As of March 31, 2024, the Company identified property and equipment, deposits, and lease assets and liabilities associated with the businesses in New York, Nevada, and Massachusetts with carrying amounts that are expected to be recovered principally through sale or disposal rather than through continuing use. The sale of these assets and liabilities is highly probable, they can be sold in their immediate condition, and the sales are expected to occur within the next twelve months.
As such, these assets and liabilities have been classified as \u201cheld for sale.\u201d Management does not believe these divestitures represent a strategic shift that has or will have a major effect on an entity\u2019s operations and financial results, and as such, none of these divestitures are considered a discontinued operation. The carrying value of these net assets did not exceed fair value less expected cost to sell, and as such, the Company recorded\u00a0no\u00a0impairment loss. Assets and liabilities held for sale are as follows:
\u00a0\u00a0\u00a0\u00a0 | \u00a0\u00a0\u00a0\u00a0 | |||||
Assets held for sale | \u00a0 | March\u00a031,\u00a0 | \u00a0\u00a0\u00a0\u00a0 | December 31, | ||
2024 | 2023 | |||||
Property and equipment | $ | 87,333,100 | $ | 86,864,965 | ||
Intangible assets | 662,500 | 662,500 | ||||
Operating lease, right-of-use asset | 3,381,612 | 3,381,612 | ||||
Deposits | 920,233 | 304,194 | ||||
Total assets held for sale | $ | 92,297,445 | $ | 91,213,271 | ||
Liabilities held for sale | \u00a0 | \u00a0\u00a0 | \u00a0 | |||
Right of Use Liability | $ | 88,373,080 | $ | 88,326,323 | ||
Total liabilities held for sale | $ | 88,373,080 | $ | 88,326,323 |
Current assets and liabilities held by our New York business have not been classified as held for sale. Pre-tax operating losses attributable to the New York business were $3,698,934\u00a0for the three months ended March 31, 2024.
"}]},{"name":"rpt:f-280","factDimensions":{"xbrl:concept":"us-gaap:ImpairmentOfLongLivedAssetsToBeDisposedOf","xbrl:period":"2024-01-01T00:00:00/2024-04-01T00:00:00","xbrl:entity":"cik:0001771706","xbrl:unit":"iso4217:USD","us-gaap:DisposalGroupClassificationAxis":"us-gaap:DisposalGroupHeldforsaleNotDiscontinuedOperationsMember"},"factValues":[{"value":"0","decimals":0}]},{"name":"rpt:f-281","factDimensions":{"xbrl:concept":"us-gaap:ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock","xbrl:period":"2024-01-01T00:00:00/2024-04-01T00:00:00","xbrl:entity":"cik:0001771706"},"factValues":[{"value":"\u00a0\u00a0\u00a0\u00a0 | \u00a0\u00a0\u00a0\u00a0 | |||||
Assets held for sale | \u00a0 | March\u00a031,\u00a0 | \u00a0\u00a0\u00a0\u00a0 | December 31, | ||
2024 | 2023 | |||||
Property and equipment | $ | 87,333,100 | $ | 86,864,965 | ||
Intangible assets | 662,500 | 662,500 | ||||
Operating lease, right-of-use asset | 3,381,612 | 3,381,612 | ||||
Deposits | 920,233 | 304,194 | ||||
Total assets held for sale | $ | 92,297,445 | $ | 91,213,271 | ||
Liabilities held for sale | \u00a0 | \u00a0\u00a0 | \u00a0 | |||
Right of Use Liability | $ | 88,373,080 | $ | 88,326,323 | ||
Total liabilities held for sale | $ | 88,373,080 | $ | 88,326,323 |
4. Fair Value Measurements
The Company complies with ASC 820, Fair Value Measurements, for its financial assets and liabilities that are re-measured and reported at fair value at each reporting period, and non-financial assets and liabilities that are re-measured and reported at fair value at least annually. In general, fair values determined by Level 1 inputs utilize quoted prices (unadjusted) in active markets for identical assets or liabilities. Fair values determined by Level 2 inputs utilize data points that are observable such as quoted prices, interest rates and yield curves. Fair values determined by Level 3 inputs are unobservable data points for the asset or liability, and includes situations where there is little, if any, market activity for the asset or liability.
Items measured at fair value on a non-recurring basis
The Company\u2019s non-financial assets, such as prepayments and other current assets, long lived assets, including property and equipment and intangible assets, are measured at fair value when there is an indicator of impairment and are recorded at fair value only when an impairment charge is recognized. No indicators of impairment existed as of March 31, 2024, and therefore no impairment charges were recorded.
The carrying value of the Company\u2019s accounts receivable, accounts payable, and accrued liabilities approximate their fair value due to their short-term nature, and the carrying value of notes receivable, long-term debt, and convertible debt approximates fair value as they bear a market rate of interest.
The carrying value of the Company\u2019s warrants held \u00a0utilize Level 3 inputs given there is no market activity for the asset. The inputs used are further described in Note 19.
"}]},{"name":"rpt:f-298","factDimensions":{"xbrl:concept":"us-gaap:AssetImpairmentCharges","xbrl:period":"2024-01-01T00:00:00/2024-04-01T00:00:00","xbrl:entity":"cik:0001771706","xbrl:unit":"iso4217:USD"},"factValues":[{"value":"0","decimals":0}]},{"name":"rpt:f-299","factDimensions":{"xbrl:concept":"us-gaap:AccountsAndNontradeReceivableTextBlock","xbrl:period":"2024-01-01T00:00:00/2024-04-01T00:00:00","xbrl:entity":"cik:0001771706"},"factValues":[{"value":"5. Accounts Receivable
Trade receivables are comprised of the following items:
March\u00a031,\u00a0 | December 31, | |||||
\u00a0\u00a0\u00a0\u00a0 | 2024 | \u00a0\u00a0\u00a0\u00a0 | 2023 | |||
Trade receivable | $ | 1,862,555 | $ | 2,256,763 | ||
Tax withholding receivable | 174,660 | 174,660 | ||||
Other | \u00a0 | 716,458 | \u00a0 | 655,217 | ||
Total | $ | 2,753,673 | $ | 3,086,640 |
Included in the trade receivables, net balance at March 31, 2024, and December 31, 2023, is an allowance for doubtful accounts of \u00a0$46,619\u00a0and $95,686 respectively.\u00a0Included in the tax withholding receivable, net balance at March 31, 2024, and December 31, 2023, is an allowance for doubtful accounts of $159,275.
"}]},{"name":"rpt:f-300","factDimensions":{"xbrl:concept":"gdnsf:ScheduleOfTradeReceivablesDisclosureTableTextBlock","xbrl:period":"2024-01-01T00:00:00/2024-04-01T00:00:00","xbrl:entity":"cik:0001771706"},"factValues":[{"value":"March\u00a031,\u00a0 | December 31, | |||||
\u00a0\u00a0\u00a0\u00a0 | 2024 | \u00a0\u00a0\u00a0\u00a0 | 2023 | |||
Trade receivable | $ | 1,862,555 | $ | 2,256,763 | ||
Tax withholding receivable | 174,660 | 174,660 | ||||
Other | \u00a0 | 716,458 | \u00a0 | 655,217 | ||
Total | $ | 2,753,673 | $ | 3,086,640 |
6. Inventory
Inventory is comprised of the following items:
\u00a0\u00a0\u00a0\u00a0 | March\u00a031,\u00a0 | December 31, | ||||
\u00a0\u00a0\u00a0\u00a0 | 2024 | \u00a0\u00a0\u00a0\u00a0 | 2023 | |||
Work-in-progress | $ | 13,154,921 | $ | 13,058,348 | ||
Finished goods | \u00a0 | 5,318,269 | \u00a0 | 5,278,331 | ||
Other | \u00a0 | 884,060 | \u00a0 | 949,191 | ||
Total | $ | 19,357,250 | $ | 19,285,870 |
Inventory is written down for any obsolescence, spoilage and excess inventory or when the net realizable value of inventory is less than the carrying value. Inventory valuation adjustments included in cost of sales on the statements of net loss and comprehensive loss is comprised of the following:
\u00a0\u00a0\u00a0\u00a0 | March\u00a031,\u00a0 | |||||
\u00a0\u00a0\u00a0\u00a0 | 2024 | \u00a0\u00a0\u00a0\u00a0 | 2023 | |||
Work-in-progress | $ | (188,200) | $ | 15,072 | ||
Finished goods | \u00a0 | (115,800) | \u00a0 | (25,072) | ||
Total | $ | (304,000) | $ | (10,000) |
"}]},{"name":"rpt:f-314","factDimensions":{"xbrl:concept":"us-gaap:ScheduleOfInventoryCurrentTableTextBlock","xbrl:period":"2024-01-01T00:00:00/2024-04-01T00:00:00","xbrl:entity":"cik:0001771706"},"factValues":[{"value":"
\u00a0\u00a0\u00a0\u00a0 | March\u00a031,\u00a0 | December 31, | ||||
\u00a0\u00a0\u00a0\u00a0 | 2024 | \u00a0\u00a0\u00a0\u00a0 | 2023 | |||
Work-in-progress | $ | 13,154,921 | $ | 13,058,348 | ||
Finished goods | \u00a0 | 5,318,269 | \u00a0 | 5,278,331 | ||
Other | \u00a0 | 884,060 | \u00a0 | 949,191 | ||
Total | $ | 19,357,250 | $ | 19,285,870 |
\u00a0\u00a0\u00a0\u00a0 | March\u00a031,\u00a0 | |||||
\u00a0\u00a0\u00a0\u00a0 | 2024 | \u00a0\u00a0\u00a0\u00a0 | 2023 | |||
Work-in-progress | $ | (188,200) | $ | 15,072 | ||
Finished goods | \u00a0 | (115,800) | \u00a0 | (25,072) | ||
Total | $ | (304,000) | $ | (10,000) |
"}]},{"name":"rpt:f-324","factDimensions":{"xbrl:concept":"gdnsf:InventoryValuationAdjustmentsWorkInProgress","xbrl:period":"2024-01-01T00:00:00/2024-04-01T00:00:00","xbrl:entity":"cik:0001771706","xbrl:unit":"iso4217:USD"},"factValues":[{"value":"-188200","decimals":0}]},{"name":"rpt:f-325","factDimensions":{"xbrl:concept":"gdnsf:InventoryValuationAdjustmentsWorkInProgress","xbrl:period":"2023-01-01T00:00:00/2023-04-01T00:00:00","xbrl:entity":"cik:0001771706","xbrl:unit":"iso4217:USD"},"factValues":[{"value":"15072","decimals":0}]},{"name":"rpt:f-326","factDimensions":{"xbrl:concept":"gdnsf:InventoryValuationAdjustmentsFinishedGoods","xbrl:period":"2024-01-01T00:00:00/2024-04-01T00:00:00","xbrl:entity":"cik:0001771706","xbrl:unit":"iso4217:USD"},"factValues":[{"value":"-115800","decimals":0}]},{"name":"rpt:f-327","factDimensions":{"xbrl:concept":"gdnsf:InventoryValuationAdjustmentsFinishedGoods","xbrl:period":"2023-01-01T00:00:00/2023-04-01T00:00:00","xbrl:entity":"cik:0001771706","xbrl:unit":"iso4217:USD"},"factValues":[{"value":"-25072","decimals":0}]},{"name":"rpt:f-328","factDimensions":{"xbrl:concept":"us-gaap:InventoryWriteDown","xbrl:period":"2024-01-01T00:00:00/2024-04-01T00:00:00","xbrl:entity":"cik:0001771706","xbrl:unit":"iso4217:USD"},"factValues":[{"value":"-304000","decimals":0}]},{"name":"rpt:f-329","factDimensions":{"xbrl:concept":"us-gaap:InventoryWriteDown","xbrl:period":"2023-01-01T00:00:00/2023-04-01T00:00:00","xbrl:entity":"cik:0001771706","xbrl:unit":"iso4217:USD"},"factValues":[{"value":"-10000","decimals":0}]},{"name":"rpt:f-330","factDimensions":{"xbrl:concept":"gdnsf:PrepaymentsAndOtherCurrentAssetsTextBlock","xbrl:period":"2024-01-01T00:00:00/2024-04-01T00:00:00","xbrl:entity":"cik:0001771706"},"factValues":[{"value":"
7. Prepayments and other current assets
Prepayments and other current assets are comprised of the following items:
\u00a0\u00a0\u00a0\u00a0 | March\u00a031,\u00a0 | December 31, | ||||
\u00a0\u00a0\u00a0\u00a0 | 2024 | \u00a0\u00a0\u00a0\u00a0 | 2023 | |||
Prepaid Insurance | $ | 641,365 | $ | 806,610 | ||
Other Prepaid Expenses | \u00a0 | 404,762 | \u00a0 | 529,624 | ||
Total | $ | 1,046,127 | $ | 1,336,234 |
"}]},{"name":"rpt:f-331","factDimensions":{"xbrl:concept":"gdnsf:ScheduleOfPrepaidExpenseAndOtherAssetsCurrentTableTextBlock","xbrl:period":"2024-01-01T00:00:00/2024-04-01T00:00:00","xbrl:entity":"cik:0001771706"},"factValues":[{"value":"
\u00a0\u00a0\u00a0\u00a0 | March\u00a031,\u00a0 | December 31, | ||||
\u00a0\u00a0\u00a0\u00a0 | 2024 | \u00a0\u00a0\u00a0\u00a0 | 2023 | |||
Prepaid Insurance | $ | 641,365 | $ | 806,610 | ||
Other Prepaid Expenses | \u00a0 | 404,762 | \u00a0 | 529,624 | ||
Total | $ | 1,046,127 | $ | 1,336,234 |
"}]},{"name":"rpt:f-332","factDimensions":{"xbrl:concept":"us-gaap:PrepaidInsurance","xbrl:period":"2024-04-01T00:00:00","xbrl:entity":"cik:0001771706","xbrl:unit":"iso4217:USD"},"factValues":[{"value":"641365","decimals":0}]},{"name":"rpt:f-333","factDimensions":{"xbrl:concept":"us-gaap:PrepaidInsurance","xbrl:period":"2024-01-01T00:00:00","xbrl:entity":"cik:0001771706","xbrl:unit":"iso4217:USD"},"factValues":[{"value":"806610","decimals":0}]},{"name":"rpt:f-334","factDimensions":{"xbrl:concept":"us-gaap:OtherPrepaidExpenseCurrent","xbrl:period":"2024-04-01T00:00:00","xbrl:entity":"cik:0001771706","xbrl:unit":"iso4217:USD"},"factValues":[{"value":"404762","decimals":0}]},{"name":"rpt:f-335","factDimensions":{"xbrl:concept":"us-gaap:OtherPrepaidExpenseCurrent","xbrl:period":"2024-01-01T00:00:00","xbrl:entity":"cik:0001771706","xbrl:unit":"iso4217:USD"},"factValues":[{"value":"529624","decimals":0}]},{"name":"rpt:f-336","factDimensions":{"xbrl:concept":"us-gaap:PrepaidExpenseAndOtherAssetsCurrent","xbrl:period":"2024-04-01T00:00:00","xbrl:entity":"cik:0001771706","xbrl:unit":"iso4217:USD"},"factValues":[{"value":"1046127","decimals":0}]},{"name":"rpt:f-337","factDimensions":{"xbrl:concept":"us-gaap:PrepaidExpenseAndOtherAssetsCurrent","xbrl:period":"2024-01-01T00:00:00","xbrl:entity":"cik:0001771706","xbrl:unit":"iso4217:USD"},"factValues":[{"value":"1336234","decimals":0}]},{"name":"rpt:f-338","factDimensions":{"xbrl:concept":"us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock","xbrl:period":"2024-01-01T00:00:00/2024-04-01T00:00:00","xbrl:entity":"cik:0001771706"},"factValues":[{"value":"
8. Property and Equipment, Net
Property and equipment, net consisted of the following:
\u00a0\u00a0\u00a0\u00a0 | March\u00a031,\u00a0 | December 31, | ||||
\u00a0\u00a0\u00a0\u00a0 | 2024 | \u00a0\u00a0\u00a0\u00a0 | 2023 | |||
Land | $ | 863,105 | $ | 863,105 | ||
Buildings and leasehold improvements | \u00a0 | 15,204,145 | \u00a0 | 15,124,915 | ||
Furniture and equipment | \u00a0 | 7,035,631 | \u00a0 | 7,807,250 | ||
Software | \u00a0 | 39,388 | \u00a0 | 242,204 | ||
Vehicles | \u00a0 | 271,769 | \u00a0 | 284,000 | ||
Construction-in-progress | \u00a0 | 986,391 | \u00a0 | 128,220 | ||
Right of use asset under finance lease | \u00a0 | 7,938,138 | \u00a0 | 7,938,138 | ||
\u00a0 | 32,338,567 | \u00a0 | 32,387,832 | |||
Less: accumulated depreciation | \u00a0 | (8,797,122) | \u00a0 | (9,096,649) | ||
Total | $ | 23,541,445 | $ | 23,291,183 |
For the three months ended March 31, 2024, and 2023, total depreciation on property and equipment was $633,728 and $893,598, respectively. For the three months ended March 31, 2024, and 2023, accumulated amortization of the right of use asset under finance lease amounted to $2,507,998 and $1,934,235, respectively. The right of use asset under finance lease of $7,938,138 consists of leased processing and cultivation premises. The Company capitalized into inventory $560,180 and $734,087 relating to depreciation associated with manufacturing equipment and production facilities for the three months ended March 31, 2024, and 2023, respectively. The capitalized depreciation costs associated are added to inventory and expensed through Cost of Sales Product Cost on the unaudited condensed consolidated statements of net loss and comprehensive loss.
As of March 31, 2024, in conjunction with the Company\u2019s held for sale assessment and disposal of certain long-lived assets, the Company evaluated whether property and equipment showed any indicators of impairment, and it was determined that the recoverable amount of certain net assets was above book value. As a result, the Company recorded no impairment charge\u00a0(2023 - $0) on property and equipment, net.
"}]},{"name":"rpt:f-339","factDimensions":{"xbrl:concept":"us-gaap:PropertyPlantAndEquipmentTextBlock","xbrl:period":"2024-01-01T00:00:00/2024-04-01T00:00:00","xbrl:entity":"cik:0001771706"},"factValues":[{"value":"\u00a0\u00a0\u00a0\u00a0 | March\u00a031,\u00a0 | December 31, | ||||
\u00a0\u00a0\u00a0\u00a0 | 2024 | \u00a0\u00a0\u00a0\u00a0 | 2023 | |||
Land | $ | 863,105 | $ | 863,105 | ||
Buildings and leasehold improvements | \u00a0 | 15,204,145 | \u00a0 | 15,124,915 | ||
Furniture and equipment | \u00a0 | 7,035,631 | \u00a0 | 7,807,250 | ||
Software | \u00a0 | 39,388 | \u00a0 | 242,204 | ||
Vehicles | \u00a0 | 271,769 | \u00a0 | 284,000 | ||
Construction-in-progress | \u00a0 | 986,391 | \u00a0 | 128,220 | ||
Right of use asset under finance lease | \u00a0 | 7,938,138 | \u00a0 | 7,938,138 | ||
\u00a0 | 32,338,567 | \u00a0 | 32,387,832 | |||
Less: accumulated depreciation | \u00a0 | (8,797,122) | \u00a0 | (9,096,649) | ||
Total | $ | 23,541,445 | $ | 23,291,183 |
9. Leases
Components of lease expenses are listed below:
\u00a0\u00a0\u00a0\u00a0 | March\u00a031,\u00a0 | March\u00a031,\u00a0 | ||||
\u00a0\u00a0\u00a0\u00a0 | 2024 | 2023 | ||||
Finance lease cost | \u00a0\u00a0 | |||||
Amortization of ROU assets | $ | 143,441 | $ | 270,935 | ||
Interest on lease liabilities | \u00a0 | 3,544,177 | \u00a0 | 2,725,966 | ||
Operating lease costs | \u00a0 | 432,444 | \u00a0 | 590,920 | ||
Total lease costs | $ | 4,120,062 | $ | 3,587,821 |
Future minimum lease payments (principal and interest) on the leases are as follows:
\u00a0\u00a0\u00a0\u00a0 | Operating\u00a0Leases | \u00a0\u00a0\u00a0\u00a0 | Finance\u00a0Leases | \u00a0\u00a0\u00a0\u00a0 | |||||
\u00a0\u00a0\u00a0\u00a0 | March 31, 2024 | \u00a0\u00a0\u00a0\u00a0 | March 31, 2024 | \u00a0\u00a0\u00a0\u00a0 | Total | ||||
2024 | $ | 1,673,583 | $ | 10,183,227 | $ | 11,856,810 | |||
2025 | \u00a0 | 3,047,603 | \u00a0 | 13,773,155 | \u00a0 | 16,820,758 | |||
2026 | \u00a0 | 2,727,346 | \u00a0 | 14,183,661 | \u00a0 | 16,911,007 | |||
2027 | \u00a0 | 2,474,144 | \u00a0 | 14,606,527 | \u00a0 | 17,080,671 | |||
2028 | \u00a0 | 2,254,049 | \u00a0 | 15,042,128 | \u00a0 | 17,296,177 | |||
Thereafter | \u00a0 | 7,824,515 | \u00a0 | 218,572,918 | \u00a0 | 226,397,433 | |||
Total minimum lease payments | $ | 20,001,240 | $ | 286,361,616 | $ | 306,362,856 | |||
Less discount to net present value | (4,750,354) | \u00a0 | (192,721,556) | \u00a0 | (197,471,910) | ||||
Less liabilities held for sale | (3,096,598) | (85,276,482) | (88,373,080) | ||||||
Present value of lease liability | $ | 12,154,288 | $ | 8,363,578 | $ | 20,517,866 |
The Company has entered into various lease agreements for the use of buildings used in production and retail sales of cannabis products.
On February 22, 2024, the Company executed a lease with its landlord on a site for cannabis cultivation and manufacturing facilities. Per the terms of the lease the landlord agreed to provide the Company with\u00a0$2,000,000\u00a0of tenant improvement allowances. Rent payments will not commence until January 1, 2025, at which time monthly base rent will be\u00a0$82,500. Starting January 1, 2025, the Company has the option to purchase the property. The initial purchase price is\u00a0$13,000,000\u00a0increasing by\u00a03%\u00a0at the start of each calendar year until the option expires on December 31, 2028. The lease expires on December 31, 2034.
On February 24, 2023, the Company signed the fourth amendment to the existing lease agreements for the cultivation and processing facilities in New York. The amendment provides for additional tenant improvements of\u00a0$4,000,000\u00a0and increases base rent by\u00a0$50,000\u00a0a month. \u00a0
Supplemental cash flow information related to leases:
\u00a0\u00a0\u00a0\u00a0 | March\u00a031,\u00a0 | |||||
\u00a0\u00a0\u00a0\u00a0 | 2024 | \u00a0\u00a0\u00a0\u00a0 | 2023 | |||
Cash paid for amounts included in the measurement of lease liabilities: | \u00a0\u00a0 | \u00a0 | \u00a0\u00a0 | |||
Lease principal payments - finance | $ | 71,066 | $ | 288,574 | ||
Lease principal payments - operating | 168,554 | \u2014 | ||||
Non-cash additions to ROU assets | \u00a0 | 9,270,915 | \u00a0 | 4,054,328 | ||
Amortization of operating leases | \u00a0 | 170,196 | \u00a0 | 309,747 |
Other information about lease amounts recognized in the financial statements:
\u00a0\u00a0\u00a0\u00a0 | March\u00a031,\u00a0 | \u00a0 | ||||
\u00a0\u00a0\u00a0\u00a0 | 2024 | \u00a0\u00a0\u00a0\u00a0 | 2023 | \u00a0 | ||
Weighted-average remaining lease term (years) \u2013 operating leases | 8.08 | \u00a0 | 4.67 | |||
Weighted-average remaining lease term (years) \u2013 finance leases | 16.82 | \u00a0 | 17.57 | |||
Weighted-average discount rate \u2013 operating leases | 8.58 | %\u00a0\u00a0 | 15.00 | % | ||
Weighted-average discount rate \u2013 finance leases | 16.21 | %\u00a0\u00a0 | 15.33 | % |
"}]},{"name":"rpt:f-370","factDimensions":{"xbrl:concept":"us-gaap:LeaseCostTableTextBlock","xbrl:period":"2024-01-01T00:00:00/2024-04-01T00:00:00","xbrl:entity":"cik:0001771706"},"factValues":[{"value":"
\u00a0\u00a0\u00a0\u00a0 | March\u00a031,\u00a0 | March\u00a031,\u00a0 | ||||
\u00a0\u00a0\u00a0\u00a0 | 2024 | 2023 | ||||
Finance lease cost | \u00a0\u00a0 | |||||
Amortization of ROU assets | $ | 143,441 | $ | 270,935 | ||
Interest on lease liabilities | \u00a0 | 3,544,177 | \u00a0 | 2,725,966 | ||
Operating lease costs | \u00a0 | 432,444 | \u00a0 | 590,920 | ||
Total lease costs | $ | 4,120,062 | $ | 3,587,821 |
\u00a0\u00a0\u00a0\u00a0 | Operating\u00a0Leases | \u00a0\u00a0\u00a0\u00a0 | Finance\u00a0Leases | \u00a0\u00a0\u00a0\u00a0 | |||||
\u00a0\u00a0\u00a0\u00a0 | March 31, 2024 | \u00a0\u00a0\u00a0\u00a0 | March 31, 2024 | \u00a0\u00a0\u00a0\u00a0 | Total | ||||
2024 | $ | 1,673,583 | $ | 10,183,227 | $ | 11,856,810 | |||
2025 | \u00a0 | 3,047,603 | \u00a0 | 13,773,155 | \u00a0 | 16,820,758 | |||
2026 | \u00a0 | 2,727,346 | \u00a0 | 14,183,661 | \u00a0 | 16,911,007 | |||
2027 | \u00a0 | 2,474,144 | \u00a0 | 14,606,527 | \u00a0 | 17,080,671 | |||
2028 | \u00a0 | 2,254,049 | \u00a0 | 15,042,128 | \u00a0 | 17,296,177 | |||
Thereafter | \u00a0 | 7,824,515 | \u00a0 | 218,572,918 | \u00a0 | 226,397,433 | |||
Total minimum lease payments | $ | 20,001,240 | $ | 286,361,616 | $ | 306,362,856 | |||
Less discount to net present value | (4,750,354) | \u00a0 | (192,721,556) | \u00a0 | (197,471,910) | ||||
Less liabilities held for sale | (3,096,598) | (85,276,482) | (88,373,080) | ||||||
Present value of lease liability | $ | 12,154,288 | $ | 8,363,578 | $ | 20,517,866 |
"}]},{"name":"rpt:f-380","factDimensions":{"xbrl:concept":"us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock","xbrl:period":"2024-01-01T00:00:00/2024-04-01T00:00:00","xbrl:entity":"cik:0001771706"},"factValues":[{"value":"
\u00a0\u00a0\u00a0\u00a0 | Operating\u00a0Leases | \u00a0\u00a0\u00a0\u00a0 | Finance\u00a0Leases | \u00a0\u00a0\u00a0\u00a0 | |||||
\u00a0\u00a0\u00a0\u00a0 | March 31, 2024 | \u00a0\u00a0\u00a0\u00a0 | March 31, 2024 | \u00a0\u00a0\u00a0\u00a0 | Total | ||||
2024 | $ | 1,673,583 | $ | 10,183,227 | $ | 11,856,810 | |||
2025 | \u00a0 | 3,047,603 | \u00a0 | 13,773,155 | \u00a0 | 16,820,758 | |||
2026 | \u00a0 | 2,727,346 | \u00a0 | 14,183,661 | \u00a0 | 16,911,007 | |||
2027 | \u00a0 | 2,474,144 | \u00a0 | 14,606,527 | \u00a0 | 17,080,671 | |||
2028 | \u00a0 | 2,254,049 | \u00a0 | 15,042,128 | \u00a0 | 17,296,177 | |||
Thereafter | \u00a0 | 7,824,515 | \u00a0 | 218,572,918 | \u00a0 | 226,397,433 | |||
Total minimum lease payments | $ | 20,001,240 | $ | 286,361,616 | $ | 306,362,856 | |||
Less discount to net present value | (4,750,354) | \u00a0 | (192,721,556) | \u00a0 | (197,471,910) | ||||
Less liabilities held for sale | (3,096,598) | (85,276,482) | (88,373,080) | ||||||
Present value of lease liability | $ | 12,154,288 | $ | 8,363,578 | $ | 20,517,866 |
\u00a0\u00a0\u00a0\u00a0 | March\u00a031,\u00a0 | |||||
\u00a0\u00a0\u00a0\u00a0 | 2024 | \u00a0\u00a0\u00a0\u00a0 | 2023 | |||
Cash paid for amounts included in the measurement of lease liabilities: | \u00a0\u00a0 | \u00a0 | \u00a0\u00a0 | |||
Lease principal payments - finance | $ | 71,066 | $ | 288,574 | ||
Lease principal payments - operating | 168,554 | \u2014 | ||||
Non-cash additions to ROU assets | \u00a0 | 9,270,915 | \u00a0 | 4,054,328 | ||
Amortization of operating leases | \u00a0 | 170,196 | \u00a0 | 309,747 |
\u00a0\u00a0\u00a0\u00a0 | March\u00a031,\u00a0 | \u00a0 | ||||
\u00a0\u00a0\u00a0\u00a0 | 2024 | \u00a0\u00a0\u00a0\u00a0 | 2023 | \u00a0 | ||
Weighted-average remaining lease term (years) \u2013 operating leases | 8.08 | \u00a0 | 4.67 | |||
Weighted-average remaining lease term (years) \u2013 finance leases | 16.82 | \u00a0 | 17.57 | |||
Weighted-average discount rate \u2013 operating leases | 8.58 | %\u00a0\u00a0 | 15.00 | % | ||
Weighted-average discount rate \u2013 finance leases | 16.21 | %\u00a0\u00a0 | 15.33 | % |
"}]},{"name":"rpt:f-426","factDimensions":{"xbrl:concept":"us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1","xbrl:period":"2024-04-01T00:00:00","xbrl:entity":"cik:0001771706"},"factValues":[{"value":"P8Y29D"}]},{"name":"rpt:f-427","factDimensions":{"xbrl:concept":"us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1","xbrl:period":"2023-04-01T00:00:00","xbrl:entity":"cik:0001771706"},"factValues":[{"value":"P4Y8M1D"}]},{"name":"rpt:f-428","factDimensions":{"xbrl:concept":"us-gaap:FinanceLeaseWeightedAverageRemainingLeaseTerm1","xbrl:period":"2024-04-01T00:00:00","xbrl:entity":"cik:0001771706"},"factValues":[{"value":"P16Y9M25D"}]},{"name":"rpt:f-429","factDimensions":{"xbrl:concept":"us-gaap:FinanceLeaseWeightedAverageRemainingLeaseTerm1","xbrl:period":"2023-04-01T00:00:00","xbrl:entity":"cik:0001771706"},"factValues":[{"value":"P17Y6M25D"}]},{"name":"rpt:f-430","factDimensions":{"xbrl:concept":"us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent","xbrl:period":"2024-04-01T00:00:00","xbrl:entity":"cik:0001771706"},"factValues":[{"value":"0.0858","decimals":4}]},{"name":"rpt:f-431","factDimensions":{"xbrl:concept":"us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent","xbrl:period":"2023-04-01T00:00:00","xbrl:entity":"cik:0001771706"},"factValues":[{"value":"0.1500","decimals":4}]},{"name":"rpt:f-432","factDimensions":{"xbrl:concept":"us-gaap:FinanceLeaseWeightedAverageDiscountRatePercent","xbrl:period":"2024-04-01T00:00:00","xbrl:entity":"cik:0001771706"},"factValues":[{"value":"0.1621","decimals":4}]},{"name":"rpt:f-433","factDimensions":{"xbrl:concept":"us-gaap:FinanceLeaseWeightedAverageDiscountRatePercent","xbrl:period":"2023-04-01T00:00:00","xbrl:entity":"cik:0001771706"},"factValues":[{"value":"0.1533","decimals":4}]},{"name":"rpt:f-434","factDimensions":{"xbrl:concept":"us-gaap:GoodwillDisclosureTextBlock","xbrl:period":"2024-01-01T00:00:00/2024-04-01T00:00:00","xbrl:entity":"cik:0001771706"},"factValues":[{"value":"
10. Goodwill
The following table shows the change in carrying amount of goodwill:
Goodwill - December 31, 2022 | \u00a0\u00a0\u00a0\u00a0 | $ | 183,836 |
Divestitures (Note 3) | \u00a0 | (183,836) | |
Goodwill - December 31, 2023 and March 31, 2024 | $ | \u2014 |
The Company has\u00a0no\u00a0goodwill as of March 31, 2024. As such, no further impairment testing procedures were performed.
"}]},{"name":"rpt:f-435","factDimensions":{"xbrl:concept":"us-gaap:ScheduleOfGoodwillTextBlock","xbrl:period":"2024-01-01T00:00:00/2024-04-01T00:00:00","xbrl:entity":"cik:0001771706"},"factValues":[{"value":"Goodwill - December 31, 2022 | \u00a0\u00a0\u00a0\u00a0 | $ | 183,836 |
Divestitures (Note 3) | \u00a0 | (183,836) | |
Goodwill - December 31, 2023 and March 31, 2024 | $ | \u2014 |
11. Intangibles
Intangible assets are comprised of the following items:
\u00a0\u00a0\u00a0\u00a0 | Licenses & Trademarks | ||
Balance, December\u00a031,\u00a02022 | $ | 8,776,946 | |
Divestitures | \u00a0 | (409,239) | |
Additions | 1,090,919 | ||
Amortization | (728,419) | ||
(11,630) | |||
Balance, December\u00a031,\u00a02023 | $ | 8,718,577 | |
Amortization | \u00a0 | (204,812) | |
Balance, March 31, 2024 | $ | 8,513,765 |
Amortization expense for intangibles was\u00a0$204,812\u00a0and\u00a0$159,766\u00a0during the three months ended March 31, 2024 and 2023, respectively. Amortization expense is recorded in operating expenses on the unaudited condensed consolidated statements of net loss and comprehensive loss.
The Company estimates that amortization expense will be $819,655 next five fiscal years.
"}]},{"name":"rpt:f-440","factDimensions":{"xbrl:concept":"gdnsf:ScheduleOfFiniteLivedAndIndefiniteLivedIntangibleAssetsByMajorClassTableTextBlock","xbrl:period":"2024-01-01T00:00:00/2024-04-01T00:00:00","xbrl:entity":"cik:0001771706"},"factValues":[{"value":"\u00a0\u00a0\u00a0\u00a0 | Licenses & Trademarks | ||
Balance, December\u00a031,\u00a02022 | $ | 8,776,946 | |
Divestitures | \u00a0 | (409,239) | |
Additions | 1,090,919 | ||
Amortization | (728,419) | ||
(11,630) | |||
Balance, December\u00a031,\u00a02023 | $ | 8,718,577 | |
Amortization | \u00a0 | (204,812) | |
Balance, March 31, 2024 | $ | 8,513,765 |
12. Accounts Payable and Accrued Liabilities
Accounts payable and accrued liabilities are comprised of the following items:
\u00a0\u00a0\u00a0\u00a0 | March\u00a031,\u00a0 | December 31, | ||||
\u00a0\u00a0\u00a0\u00a0 | 2024 | \u00a0\u00a0\u00a0\u00a0 | 2023 | |||
Accounts payable \u2013 trade | $ | 2,111,125 | $ | 1,769,346 | ||
Accrued Expenses | \u00a0 | 4,626,887 | \u00a0 | 4,852,648 | ||
Taxes payable | \u00a0 | 346,450 | \u00a0 | 218,563 | ||
Contract liability | \u00a0 | 885,696 | \u00a0 | 833,832 | ||
Total accounts payable and accrued liabilities | $ | 7,970,158 | $ | 7,674,389 |
"}]},{"name":"rpt:f-453","factDimensions":{"xbrl:concept":"us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock","xbrl:period":"2024-01-01T00:00:00/2024-04-01T00:00:00","xbrl:entity":"cik:0001771706"},"factValues":[{"value":"
\u00a0\u00a0\u00a0\u00a0 | March\u00a031,\u00a0 | December 31, | ||||
\u00a0\u00a0\u00a0\u00a0 | 2024 | \u00a0\u00a0\u00a0\u00a0 | 2023 | |||
Accounts payable \u2013 trade | $ | 2,111,125 | $ | 1,769,346 | ||
Accrued Expenses | \u00a0 | 4,626,887 | \u00a0 | 4,852,648 | ||
Taxes payable | \u00a0 | 346,450 | \u00a0 | 218,563 | ||
Contract liability | \u00a0 | 885,696 | \u00a0 | 833,832 | ||
Total accounts payable and accrued liabilities | $ | 7,970,158 | $ | 7,674,389 |
"}]},{"name":"rpt:f-454","factDimensions":{"xbrl:concept":"us-gaap:AccountsPayableTradeCurrent","xbrl:period":"2024-04-01T00:00:00","xbrl:entity":"cik:0001771706","xbrl:unit":"iso4217:USD"},"factValues":[{"value":"2111125","decimals":0}]},{"name":"rpt:f-455","factDimensions":{"xbrl:concept":"us-gaap:AccountsPayableTradeCurrent","xbrl:period":"2024-01-01T00:00:00","xbrl:entity":"cik:0001771706","xbrl:unit":"iso4217:USD"},"factValues":[{"value":"1769346","decimals":0}]},{"name":"rpt:f-456","factDimensions":{"xbrl:concept":"us-gaap:AccruedLiabilitiesCurrent","xbrl:period":"2024-04-01T00:00:00","xbrl:entity":"cik:0001771706","xbrl:unit":"iso4217:USD"},"factValues":[{"value":"4626887","decimals":0}]},{"name":"rpt:f-457","factDimensions":{"xbrl:concept":"us-gaap:AccruedLiabilitiesCurrent","xbrl:period":"2024-01-01T00:00:00","xbrl:entity":"cik:0001771706","xbrl:unit":"iso4217:USD"},"factValues":[{"value":"4852648","decimals":0}]},{"name":"rpt:f-458","factDimensions":{"xbrl:concept":"us-gaap:TaxesPayableCurrent","xbrl:period":"2024-04-01T00:00:00","xbrl:entity":"cik:0001771706","xbrl:unit":"iso4217:USD"},"factValues":[{"value":"346450","decimals":0}]},{"name":"rpt:f-459","factDimensions":{"xbrl:concept":"us-gaap:TaxesPayableCurrent","xbrl:period":"2024-01-01T00:00:00","xbrl:entity":"cik:0001771706","xbrl:unit":"iso4217:USD"},"factValues":[{"value":"218563","decimals":0}]},{"name":"rpt:f-460","factDimensions":{"xbrl:concept":"us-gaap:ContractWithCustomerLiabilityCurrent","xbrl:period":"2024-04-01T00:00:00","xbrl:entity":"cik:0001771706","xbrl:unit":"iso4217:USD"},"factValues":[{"value":"885696","decimals":0}]},{"name":"rpt:f-461","factDimensions":{"xbrl:concept":"us-gaap:ContractWithCustomerLiabilityCurrent","xbrl:period":"2024-01-01T00:00:00","xbrl:entity":"cik:0001771706","xbrl:unit":"iso4217:USD"},"factValues":[{"value":"833832","decimals":0}]},{"name":"rpt:f-462","factDimensions":{"xbrl:concept":"us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent","xbrl:period":"2024-04-01T00:00:00","xbrl:entity":"cik:0001771706","xbrl:unit":"iso4217:USD"},"factValues":[{"value":"7970158","decimals":0}]},{"name":"rpt:f-463","factDimensions":{"xbrl:concept":"us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent","xbrl:period":"2024-01-01T00:00:00","xbrl:entity":"cik:0001771706","xbrl:unit":"iso4217:USD"},"factValues":[{"value":"7674389","decimals":0}]},{"name":"rpt:f-464","factDimensions":{"xbrl:concept":"gdnsf:LongTermDebtExcludingConvertibleDebtTextBlock","xbrl:period":"2024-01-01T00:00:00/2024-04-01T00:00:00","xbrl:entity":"cik:0001771706"},"factValues":[{"value":"
13. Long-Term Debt
During 2017 the Company signed a promissory note payable in the amount of\u00a0$1,010,000. The note bears interest at a rate of\u00a015%\u00a0per annum with interest payments required on a\u00a0monthly\u00a0basis. In 2019 the Company\u2019s promissory note payable in the amount of\u00a0$1,010,000\u00a0was modified to increase the amount payable to\u00a0$1,110,000. The Company repaid the note in full during the three months ended March 31, 2024.
On November 19, 2021, the Company signed a promissory note payable in the amount of $2,000,000\u00a0in connection with the acquisition of Charm City Medicus, LLC. The note bears an interest rate of\u00a08% per annum with interest payments due
on the last day of each calendar\u00a0quarter. On November 19, 2023, the Company and lender amended the note. Per the terms of the amendment, the interest rate was modified to\u00a015%, and the Company paid off $1,000,000\u00a0of principal. \u00a0The remaining principal balance of $1,000,000\u00a0is due on\u00a0November 19, 2024, and the note is secured by\u00a025% of the membership interests in Vireo Health of Charm City, LLC.
On March 25, 2021, the Company entered into a credit agreement for a senior secured delayed draw term loan with an aggregate principal amount of up to $46,000,000\u00a0(the \u201cCredit Facility\u201d), and executed a draw of $26,000,000\u00a0in principal. The unpaid principal amounts outstanding under the Credit Facility bear interest at a rate of (a)\u00a0the U.S. prime rate plus\u00a010.375%, payable monthly in cash, and (b)\u00a02.75% per annum paid in kind (\u201cPIK\u201d) interest payable monthly. In connection with the Credit Facility, the Company also pays a monthly credit monitoring fee in the amount of $130,400\u00a0which is included in interest expense in the consolidated statements of loss and comprehensive loss for the three months ended March 31, 2024 and 2023.The Credit Facility matures on March 31, 2024.
On November 18, 2021, the Company and lenders amended the Credit Facility to provide for an additional loan of $4,200,000\u00a0with a cash interest rate of\u00a015% per annum and PIK interest of\u00a02% per annum and a maturity date of November 29, 2024. Obligations under the Credit Facility are secured by substantially all the assets of the Company.
On January 31, 2022, Goodness Growth and certain of its subsidiaries, as borrowers (collectively, \u201cBorrowers\u201d), entered into a Third Amendment to the Credit Facility (the \u201cThird Amendment\u201d) providing for additional delayed draw term loans of up to\u00a0$55\u00a0million (the \u201cDelayed Draw Loans\u201d). The cash interest rate on the Delayed Draw Loans under the Third Amendment is equal to the U.S. prime rate plus\u00a010.375%, with a minimum required rate of\u00a013.375%\u00a0per annum, in addition to PIK interest of\u00a02.75%\u00a0per annum.
On March 31, 2023, the Company executed a fifth amendment to its Credit Facility with its senior secured lender, Chicago Atlantic Admin, LLC (the \"Agent\"), an affiliate of Green Ivy Capital, and a group of lenders. The amended credit facility extends the maturity date on its Delayed Draw Loans to April 30, 2024, through the issuance of\u00a015,000,000\u00a0Subordinate Voting Shares in lieu of a cash extension fee. These\u00a015,000,000\u00a0shares were valued at $1,407,903\u00a0using a fair value per share of $0.094\u00a0and considered a deferred financing cost. The fair value per share reflects a\u00a022% discount to the market price at the time of issuance to account for the\u00a0four-month\u00a0trading lock-up imposed on the shares. The amendment also provides the Company with reduced cash outlays by eliminating required amortization of the loan, and requires the Company to divest certain assets to improve its liquidity position and financial performance. The Company has the potential to extend the maturity date on its Delayed Draw Loans up to January 31, 2026 with the satisfaction of certain financial performance-related conditions.
Unless otherwise specified, all deferred financing costs are treated as a contra-liability, to be netted against the outstanding loan balance and amortized over the remaining life of the loan. As of March 31, 2024, $201,015\u00a0(December 31, 2023 - $1,524,531) of deferred financing costs remain unamortized.
The following table shows a summary of the Company\u2019s long-term debt:
\u00a0\u00a0\u00a0\u00a0 | March\u00a031,\u00a0 | December 31, | ||||
\u00a0\u00a0\u00a0\u00a0 | 2024 | \u00a0\u00a0\u00a0\u00a0 | 2023 | |||
Beginning of year | $ | 60,220,535 | $ | 58,028,604 | ||
Principal repayments | (1,050,000) | (2,976,362) | ||||
Deferred financing costs | \u2014 | (1,407,903) | ||||
PIK interest | 1,323,516 | 1,607,032 | ||||
Amortization of deferred financing costs | 402,237 | 4,969,164 | ||||
End of period | \u00a0 | 60,896,288 | \u00a0 | 60,220,535 | ||
Less: current portion | \u00a0 | 60,896,288 | \u00a0 | 60,220,535 | ||
Total long-term debt | $ | \u2014 | $ | \u2014 |
As of March 31, 2024, stated maturities of long-term debt were as follows:
2024 | $ | 60,896,288 | |
Total | $ | 60,896,288 |
"}]},{"name":"rpt:f-465","factDimensions":{"xbrl:concept":"us-gaap:DebtInstrumentFaceAmount","xbrl:period":"2018-01-01T00:00:00","xbrl:entity":"cik:0001771706","xbrl:unit":"iso4217:USD","us-gaap:LongtermDebtTypeAxis":"us-gaap:NotesPayableOtherPayablesMember"},"factValues":[{"value":"1010000","decimals":0}]},{"name":"rpt:f-466","factDimensions":{"xbrl:concept":"us-gaap:DebtInstrumentInterestRateStatedPercentage","xbrl:period":"2018-01-01T00:00:00","xbrl:entity":"cik:0001771706","us-gaap:LongtermDebtTypeAxis":"us-gaap:NotesPayableOtherPayablesMember"},"factValues":[{"value":"0.15","decimals":2}]},{"name":"rpt:f-467","factDimensions":{"xbrl:concept":"us-gaap:DebtInstrumentFrequencyOfPeriodicPayment","xbrl:period":"2017-01-01T00:00:00/2018-01-01T00:00:00","xbrl:entity":"cik:0001771706","us-gaap:LongtermDebtTypeAxis":"us-gaap:NotesPayableOtherPayablesMember"},"factValues":[{"value":"monthly"}]},{"name":"rpt:f-468","factDimensions":{"xbrl:concept":"us-gaap:DebtInstrumentFaceAmount","xbrl:period":"2018-01-01T00:00:00","xbrl:entity":"cik:0001771706","xbrl:unit":"iso4217:USD","us-gaap:LongtermDebtTypeAxis":"us-gaap:NotesPayableOtherPayablesMember"},"factValues":[{"value":"1010000","decimals":0}]},{"name":"rpt:f-469","factDimensions":{"xbrl:concept":"us-gaap:DebtInstrumentFaceAmount","xbrl:period":"2020-01-01T00:00:00","xbrl:entity":"cik:0001771706","xbrl:unit":"iso4217:USD","us-gaap:LongtermDebtTypeAxis":"us-gaap:NotesPayableOtherPayablesMember"},"factValues":[{"value":"1110000","decimals":0}]},{"name":"rpt:f-470","factDimensions":{"xbrl:concept":"us-gaap:DebtInstrumentFaceAmount","xbrl:period":"2021-11-20T00:00:00","xbrl:entity":"cik:0001771706","xbrl:unit":"iso4217:USD","us-gaap:AssetAcquisitionAxis":"gdnsf:CharmCityMedicusLlcMember","us-gaap:LongtermDebtTypeAxis":"us-gaap:NotesPayableOtherPayablesMember"},"factValues":[{"value":"2000000","decimals":0}]},{"name":"rpt:f-471","factDimensions":{"xbrl:concept":"us-gaap:DebtInstrumentInterestRateStatedPercentage","xbrl:period":"2021-11-20T00:00:00","xbrl:entity":"cik:0001771706","us-gaap:AssetAcquisitionAxis":"gdnsf:CharmCityMedicusLlcMember","us-gaap:LongtermDebtTypeAxis":"us-gaap:NotesPayableOtherPayablesMember"},"factValues":[{"value":"0.08","decimals":2}]},{"name":"rpt:f-472","factDimensions":{"xbrl:concept":"us-gaap:DebtInstrumentInterestRateStatedPercentage","xbrl:period":"2023-11-20T00:00:00","xbrl:entity":"cik:0001771706","us-gaap:AssetAcquisitionAxis":"gdnsf:CharmCityMedicusLlcMember","us-gaap:LongtermDebtTypeAxis":"us-gaap:NotesPayableOtherPayablesMember"},"factValues":[{"value":"0.15","decimals":2}]},{"name":"rpt:f-473","factDimensions":{"xbrl:concept":"us-gaap:RepaymentsOfLongTermDebt","xbrl:period":"2023-11-19T00:00:00/2023-11-20T00:00:00","xbrl:entity":"cik:0001771706","xbrl:unit":"iso4217:USD","us-gaap:AssetAcquisitionAxis":"gdnsf:CharmCityMedicusLlcMember","us-gaap:LongtermDebtTypeAxis":"us-gaap:NotesPayableOtherPayablesMember"},"factValues":[{"value":"1000000","decimals":0}]},{"name":"rpt:f-474","factDimensions":{"xbrl:concept":"us-gaap:SecuredDebtCurrent","xbrl:period":"2023-11-20T00:00:00","xbrl:entity":"cik:0001771706","xbrl:unit":"iso4217:USD","us-gaap:AssetAcquisitionAxis":"gdnsf:CharmCityMedicusLlcMember","us-gaap:LongtermDebtTypeAxis":"us-gaap:NotesPayableOtherPayablesMember"},"factValues":[{"value":"1000000","decimals":0}]},{"name":"rpt:f-475","factDimensions":{"xbrl:concept":"us-gaap:DebtInstrumentMaturityDate","xbrl:period":"2023-11-19T00:00:00/2023-11-20T00:00:00","xbrl:entity":"cik:0001771706","us-gaap:AssetAcquisitionAxis":"gdnsf:CharmCityMedicusLlcMember","us-gaap:LongtermDebtTypeAxis":"us-gaap:NotesPayableOtherPayablesMember"},"factValues":[{"value":"2024-11-19"}]},{"name":"rpt:f-476","factDimensions":{"xbrl:concept":"gdnsf:PercentageOfMembershipInterestHeldAsCollateral","xbrl:period":"2023-11-19T00:00:00/2023-11-20T00:00:00","xbrl:entity":"cik:0001771706","us-gaap:AssetAcquisitionAxis":"gdnsf:CharmCityMedicusLlcMember","us-gaap:LongtermDebtTypeAxis":"us-gaap:LineOfCreditMember"},"factValues":[{"value":"0.25","decimals":2}]},{"name":"rpt:f-477","factDimensions":{"xbrl:concept":"us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity","xbrl:period":"2021-03-26T00:00:00","xbrl:entity":"cik:0001771706","xbrl:unit":"iso4217:USD","us-gaap:LongtermDebtTypeAxis":"us-gaap:LineOfCreditMember"},"factValues":[{"value":"46000000","decimals":0}]},{"name":"rpt:f-478","factDimensions":{"xbrl:concept":"us-gaap:ProceedsFromLinesOfCredit","xbrl:period":"2021-03-25T00:00:00/2021-03-26T00:00:00","xbrl:entity":"cik:0001771706","xbrl:unit":"iso4217:USD","us-gaap:LongtermDebtTypeAxis":"us-gaap:LineOfCreditMember"},"factValues":[{"value":"26000000","decimals":0}]},{"name":"rpt:f-479","factDimensions":{"xbrl:concept":"us-gaap:DebtInstrumentBasisSpreadOnVariableRate1","xbrl:period":"2021-03-25T00:00:00/2021-03-26T00:00:00","xbrl:entity":"cik:0001771706","us-gaap:LongtermDebtTypeAxis":"us-gaap:LineOfCreditMember","us-gaap:VariableRateAxis":"us-gaap:PrimeRateMember"},"factValues":[{"value":"0.10375","decimals":5}]},{"name":"rpt:f-480","factDimensions":{"xbrl:concept":"gdnsf:DebtInstrumentInterestInKindRatePercentage","xbrl:period":"2021-03-25T00:00:00/2021-03-26T00:00:00","xbrl:entity":"cik:0001771706","us-gaap:LongtermDebtTypeAxis":"us-gaap:LineOfCreditMember"},"factValues":[{"value":"0.0275","decimals":4}]},{"name":"rpt:f-481","factDimensions":{"xbrl:concept":"gdnsf:LineOfCreditFacilityCreditMonitoringFees","xbrl:period":"2023-01-01T00:00:00/2023-04-01T00:00:00","xbrl:entity":"cik:0001771706","xbrl:unit":"iso4217:USD","us-gaap:IncomeStatementLocationAxis":"us-gaap:InterestExpenseMember","us-gaap:LongtermDebtTypeAxis":"us-gaap:LineOfCreditMember"},"factValues":[{"value":"130400","decimals":0}]},{"name":"rpt:f-482","factDimensions":{"xbrl:concept":"gdnsf:LineOfCreditFacilityCreditMonitoringFees","xbrl:period":"2024-01-01T00:00:00/2024-04-01T00:00:00","xbrl:entity":"cik:0001771706","xbrl:unit":"iso4217:USD","us-gaap:IncomeStatementLocationAxis":"us-gaap:InterestExpenseMember","us-gaap:LongtermDebtTypeAxis":"us-gaap:LineOfCreditMember"},"factValues":[{"value":"130400","decimals":0}]},{"name":"rpt:f-483","factDimensions":{"xbrl:concept":"us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity","xbrl:period":"2021-11-19T00:00:00","xbrl:entity":"cik:0001771706","xbrl:unit":"iso4217:USD","us-gaap:LongtermDebtTypeAxis":"us-gaap:LineOfCreditMember"},"factValues":[{"value":"4200000","decimals":0}]},{"name":"rpt:f-484","factDimensions":{"xbrl:concept":"us-gaap:DebtInstrumentInterestRateStatedPercentage","xbrl:period":"2021-11-19T00:00:00","xbrl:entity":"cik:0001771706","us-gaap:LongtermDebtTypeAxis":"us-gaap:LineOfCreditMember"},"factValues":[{"value":"0.15","decimals":2}]},{"name":"rpt:f-485","factDimensions":{"xbrl:concept":"gdnsf:DebtInstrumentInterestInKindRatePercentage","xbrl:period":"2021-11-18T00:00:00/2021-11-19T00:00:00","xbrl:entity":"cik:0001771706","us-gaap:LongtermDebtTypeAxis":"us-gaap:LineOfCreditMember"},"factValues":[{"value":"0.02","decimals":2}]},{"name":"rpt:f-486","factDimensions":{"xbrl:concept":"us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity","xbrl:period":"2022-02-01T00:00:00","xbrl:entity":"cik:0001771706","xbrl:unit":"iso4217:USD","srt:RangeAxis":"srt:MaximumMember","us-gaap:TypeOfArrangementAxis":"gdnsf:ArrangementAgreementWithVeranoHoldingsCorpMember"},"factValues":[{"value":"55000000","decimals":-6}]},{"name":"rpt:f-487","factDimensions":{"xbrl:concept":"us-gaap:DebtInstrumentBasisSpreadOnVariableRate1","xbrl:period":"2022-01-31T00:00:00/2022-02-01T00:00:00","xbrl:entity":"cik:0001771706","us-gaap:TypeOfArrangementAxis":"gdnsf:ArrangementAgreementWithVeranoHoldingsCorpMember","us-gaap:VariableRateAxis":"us-gaap:PrimeRateMember"},"factValues":[{"value":"0.10375","decimals":5}]},{"name":"rpt:f-488","factDimensions":{"xbrl:concept":"us-gaap:DebtInstrumentInterestRateStatedPercentage","xbrl:period":"2022-02-01T00:00:00","xbrl:entity":"cik:0001771706","us-gaap:TypeOfArrangementAxis":"gdnsf:ArrangementAgreementWithVeranoHoldingsCorpMember"},"factValues":[{"value":"0.13375","decimals":5}]},{"name":"rpt:f-489","factDimensions":{"xbrl:concept":"gdnsf:DebtInstrumentInterestInKindRatePercentage","xbrl:period":"2022-01-31T00:00:00/2022-02-01T00:00:00","xbrl:entity":"cik:0001771706","us-gaap:TypeOfArrangementAxis":"gdnsf:ArrangementAgreementWithVeranoHoldingsCorpMember"},"factValues":[{"value":"0.0275","decimals":4}]},{"name":"rpt:f-490","factDimensions":{"xbrl:concept":"us-gaap:StockIssuedDuringPeriodSharesNewIssues","xbrl:period":"2023-03-31T00:00:00/2023-04-01T00:00:00","xbrl:entity":"cik:0001771706","xbrl:unit":"xbrla:shares","us-gaap:StatementClassOfStockAxis":"gdnsf:SubordinateVotingSharesMember"},"factValues":[{"value":"15000000"}]},{"name":"rpt:f-491","factDimensions":{"xbrl:concept":"gdnsf:SharesIssuableAccruedAsDeferredFinancing","xbrl:period":"2023-04-01T00:00:00","xbrl:entity":"cik:0001771706","xbrl:unit":"xbrla:shares","us-gaap:LongtermDebtTypeAxis":"us-gaap:LineOfCreditMember"},"factValues":[{"value":"15000000"}]},{"name":"rpt:f-492","factDimensions":{"xbrl:concept":"us-gaap:PaymentsOfFinancingCosts","xbrl:period":"2023-03-31T00:00:00/2023-04-01T00:00:00","xbrl:entity":"cik:0001771706","xbrl:unit":"iso4217:USD","us-gaap:LongtermDebtTypeAxis":"us-gaap:LineOfCreditMember"},"factValues":[{"value":"1407903","decimals":0}]},{"name":"rpt:f-493","factDimensions":{"xbrl:concept":"us-gaap:SharesIssuedPricePerShare","xbrl:period":"2023-04-01T00:00:00","xbrl:entity":"cik:0001771706","xbrl:unit":"iso4217:USD/xbrla:shares","us-gaap:LongtermDebtTypeAxis":"us-gaap:LineOfCreditMember"},"factValues":[{"value":"0.094","decimals":3}]},{"name":"rpt:f-494","factDimensions":{"xbrl:concept":"gdnsf:DebtInstrumentPercentageOfDiscountToMarketPrice","xbrl:period":"2023-03-31T00:00:00/2023-04-01T00:00:00","xbrl:entity":"cik:0001771706","us-gaap:LongtermDebtTypeAxis":"us-gaap:LineOfCreditMember"},"factValues":[{"value":"0.22","decimals":2}]},{"name":"rpt:f-495","factDimensions":{"xbrl:concept":"gdnsf:TradingLockUpPeriod","xbrl:period":"2023-03-31T00:00:00/2023-04-01T00:00:00","xbrl:entity":"cik:0001771706","us-gaap:LongtermDebtTypeAxis":"us-gaap:LineOfCreditMember"},"factValues":[{"value":"P4M"}]},{"name":"rpt:f-496","factDimensions":{"xbrl:concept":"us-gaap:DeferredFinanceCostsNet","xbrl:period":"2024-02-01T00:00:00","xbrl:entity":"cik:0001771706","xbrl:unit":"iso4217:USD","us-gaap:DebtInstrumentAxis":"us-gaap:LongTermDebtMember"},"factValues":[{"value":"201015","decimals":0}]},{"name":"rpt:f-497","factDimensions":{"xbrl:concept":"us-gaap:DeferredFinanceCostsNet","xbrl:period":"2024-01-01T00:00:00","xbrl:entity":"cik:0001771706","xbrl:unit":"iso4217:USD","us-gaap:DebtInstrumentAxis":"us-gaap:LongTermDebtMember"},"factValues":[{"value":"1524531","decimals":0}]},{"name":"rpt:f-498","factDimensions":{"xbrl:concept":"us-gaap:ScheduleOfDebtInstrumentsTextBlock","xbrl:period":"2024-01-01T00:00:00/2024-04-01T00:00:00","xbrl:entity":"cik:0001771706"},"factValues":[{"value":"
\u00a0\u00a0\u00a0\u00a0 | March\u00a031,\u00a0 | December 31, | ||||
\u00a0\u00a0\u00a0\u00a0 | 2024 | \u00a0\u00a0\u00a0\u00a0 | 2023 | |||
Beginning of year | $ | 60,220,535 | $ | 58,028,604 | ||
Principal repayments | (1,050,000) | (2,976,362) | ||||
Deferred financing costs | \u2014 | (1,407,903) | ||||
PIK interest | 1,323,516 | 1,607,032 | ||||
Amortization of deferred financing costs | 402,237 | 4,969,164 | ||||
End of period | \u00a0 | 60,896,288 | \u00a0 | 60,220,535 | ||
Less: current portion | \u00a0 | 60,896,288 | \u00a0 | 60,220,535 | ||
Total long-term debt | $ | \u2014 | $ | \u2014 |
2024 | $ | 60,896,288 | |
Total | $ | 60,896,288 |
"}]},{"name":"rpt:f-513","factDimensions":{"xbrl:concept":"us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths","xbrl:period":"2024-04-01T00:00:00","xbrl:entity":"cik:0001771706","xbrl:unit":"iso4217:USD","us-gaap:LongtermDebtTypeAxis":"gdnsf:PromissoryNoteAndLineOfCreditMember"},"factValues":[{"value":"60896288","decimals":0}]},{"name":"rpt:f-514","factDimensions":{"xbrl:concept":"us-gaap:SecuredDebt","xbrl:period":"2024-04-01T00:00:00","xbrl:entity":"cik:0001771706","xbrl:unit":"iso4217:USD","us-gaap:LongtermDebtTypeAxis":"gdnsf:PromissoryNoteAndLineOfCreditMember"},"factValues":[{"value":"60896288","decimals":0}]},{"name":"rpt:f-515","factDimensions":{"xbrl:concept":"gdnsf:ConvertibleDebtTextBlock","xbrl:period":"2024-01-01T00:00:00/2024-04-01T00:00:00","xbrl:entity":"cik:0001771706"},"factValues":[{"value":"
14. Convertible Notes
On April 28, 2023, the Company closed on a new convertible debt facility which enables the Company to access up to\u00a0$10,000,000\u00a0in aggregate principal amount of convertible notes (the \u201cConvertible Notes\u201d). The convertible facility has a term of\u00a0three years, with an annual interest rate of\u00a012.0%, comprised of\u00a06.0%\u00a0cash and\u00a06.0%\u00a0PIK. The initial tranche's principal amount of Convertible Notes outstanding in the amount of\u00a0$2,000,000, plus all PIK and all other accrued but unpaid interest thereunder, is convertible into Subordinate Voting Shares of the Company at the option of the holders at any time by written notice to the Company, at a conversion price equal to\u00a0$0.145. For each future tranche advanced, the principal amount of Convertible Notes outstanding, plus all paid-in-kind interest and all other accrued but unpaid interest thereunder, is convertible into Subordinate Voting Shares of the Company at the option of the holders at any time by written notice to the Company, at a conversion price equal to the lesser of\u00a0$0.145\u00a0or a\u00a020.0%\u00a0premium over the 30-day volume weighted average price of the Company\u2019s Subordinate Voting Shares calculated on the day prior to the date on which each tranche is advanced, if permitted by the Canadian Securities Exchange. The lenders also have the right to advance any remaining undrawn funds on the convertible loan facility to the Company at any time. If the notes are not converted, the outstanding principal amount and unpaid PIK interest is due on April 30, 2026.
During the year ended December 31, 2023, the Company closed\u00a0eight\u00a0additional tranches of Convertible Notes, which are convertible into Subordinate Voting Shares at a conversion price of\u00a0$0.145. Total proceeds received from these tranches amounted to\u00a0$8,000,000.
In connection with this financing, the Company issued\u00a06,250,000\u00a0warrants to purchase Subordinate Voting Shares of the Company to the lenders. These warrants have a\u00a0five year\u00a0term, a strike price of\u00a0$0.145, and were valued at\u00a0$497,055. The value of these warrants and other legal and administrative expenses amounting to\u00a0$1,346,793\u00a0are treated as deferred financing costs.\u00a0All deferred financing costs are treated as a contra-liability, to be netted against the outstanding loan balance and amortized over the remaining life of the loan. As of \u00a0March 31, 2024 $967,587\u00a0(December 31, 2023 - $1,083,697)\u00a0of deferred financing costs remain unamortized.
The following table shows a summary of the Company\u2019s convertible debt:
\u00a0\u00a0\u00a0\u00a0 | March\u00a031,\u00a0 | December 31, | ||||
\u00a0\u00a0\u00a0\u00a0 | 2024 | \u00a0\u00a0\u00a0\u00a0 | 2023 | |||
Beginning of year | $ | 9,140,257 | $ | \u2014 | ||
Proceeds | \u00a0 | \u2014 | \u00a0 | 10,000,000 | ||
Deferred financing costs | \u2014 | (1,346,793) | ||||
PIK interest | 153,686 | 223,954 | ||||
Amortization of deferred financing costs | 116,110 | 263,096 | ||||
End of year | $ | 9,410,053 | \u00a0 | 9,140,257 | ||
Less: current portion | \u00a0 | \u2014 | \u00a0 | \u2014 | ||
Total convertible debt | $ | 9,410,053 | $ | 9,140,257 |
"}]},{"name":"rpt:f-516","factDimensions":{"xbrl:concept":"us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity","xbrl:period":"2023-04-29T00:00:00","xbrl:entity":"cik:0001771706","xbrl:unit":"iso4217:USD","us-gaap:LongtermDebtTypeAxis":"us-gaap:ConvertibleDebtMember"},"factValues":[{"value":"10000000","decimals":0}]},{"name":"rpt:f-517","factDimensions":{"xbrl:concept":"us-gaap:DebtInstrumentTerm","xbrl:period":"2023-04-28T00:00:00/2023-04-29T00:00:00","xbrl:entity":"cik:0001771706","us-gaap:LongtermDebtTypeAxis":"us-gaap:ConvertibleDebtMember"},"factValues":[{"value":"P3Y"}]},{"name":"rpt:f-518","factDimensions":{"xbrl:concept":"us-gaap:DebtInstrumentInterestRateStatedPercentage","xbrl:period":"2023-04-29T00:00:00","xbrl:entity":"cik:0001771706","us-gaap:LongtermDebtTypeAxis":"us-gaap:ConvertibleDebtMember"},"factValues":[{"value":"0.120","decimals":3}]},{"name":"rpt:f-519","factDimensions":{"xbrl:concept":"gdnsf:DebtInstrumentCashInterestRate","xbrl:period":"2023-04-28T00:00:00/2023-04-29T00:00:00","xbrl:entity":"cik:0001771706","us-gaap:LongtermDebtTypeAxis":"us-gaap:ConvertibleDebtMember"},"factValues":[{"value":"0.060","decimals":3}]},{"name":"rpt:f-520","factDimensions":{"xbrl:concept":"gdnsf:DebtInstrumentInterestInKindRatePercentage","xbrl:period":"2023-04-28T00:00:00/2023-04-29T00:00:00","xbrl:entity":"cik:0001771706","us-gaap:LongtermDebtTypeAxis":"us-gaap:ConvertibleDebtMember"},"factValues":[{"value":"0.060","decimals":3}]},{"name":"rpt:f-521","factDimensions":{"xbrl:concept":"us-gaap:DebtConversionConvertedInstrumentAmount1","xbrl:period":"2023-04-28T00:00:00/2023-04-29T00:00:00","xbrl:entity":"cik:0001771706","xbrl:unit":"iso4217:USD","us-gaap:LongtermDebtTypeAxis":"gdnsf:ConvertibleDebtTranche1Member"},"factValues":[{"value":"2000000","decimals":0}]},{"name":"rpt:f-522","factDimensions":{"xbrl:concept":"us-gaap:DebtInstrumentConvertibleConversionPrice1","xbrl:period":"2023-04-29T00:00:00","xbrl:entity":"cik:0001771706","xbrl:unit":"iso4217:USD/xbrla:shares","us-gaap:LongtermDebtTypeAxis":"gdnsf:ConvertibleDebtTranche1Member"},"factValues":[{"value":"0.145","decimals":3}]},{"name":"rpt:f-523","factDimensions":{"xbrl:concept":"us-gaap:DebtInstrumentConvertibleConversionPrice1","xbrl:period":"2023-04-29T00:00:00","xbrl:entity":"cik:0001771706","xbrl:unit":"iso4217:USD/xbrla:shares","srt:RangeAxis":"srt:MaximumMember","us-gaap:LongtermDebtTypeAxis":"gdnsf:ConvertibleDebtTranches2And3Member"},"factValues":[{"value":"0.145","decimals":3}]},{"name":"rpt:f-524","factDimensions":{"xbrl:concept":"gdnsf:DebtInstrumentConvertibleConversionPremiumOverSharePrice","xbrl:period":"2023-04-28T00:00:00/2023-04-29T00:00:00","xbrl:entity":"cik:0001771706","srt:RangeAxis":"srt:MaximumMember","us-gaap:LongtermDebtTypeAxis":"gdnsf:ConvertibleDebtTranches2And3Member"},"factValues":[{"value":"20.0","decimals":1}]},{"name":"rpt:f-525","factDimensions":{"xbrl:concept":"gdnsf:DebtInstrumentNumberOfAdditionalTranches","xbrl:period":"2023-01-01T00:00:00/2024-01-01T00:00:00","xbrl:entity":"cik:0001771706","xbrl:unit":"gdnsf:tranche","us-gaap:LongtermDebtTypeAxis":"us-gaap:ConvertibleDebtMember"},"factValues":[{"value":"8"}]},{"name":"rpt:f-526","factDimensions":{"xbrl:concept":"us-gaap:DebtInstrumentConvertibleConversionPrice1","xbrl:period":"2024-01-01T00:00:00","xbrl:entity":"cik:0001771706","xbrl:unit":"iso4217:USD/xbrla:shares","us-gaap:LongtermDebtTypeAxis":"us-gaap:ConvertibleDebtMember"},"factValues":[{"value":"0.145","decimals":3}]},{"name":"rpt:f-527","factDimensions":{"xbrl:concept":"us-gaap:DebtConversionConvertedInstrumentAmount1","xbrl:period":"2023-01-01T00:00:00/2024-01-01T00:00:00","xbrl:entity":"cik:0001771706","xbrl:unit":"iso4217:USD","us-gaap:LongtermDebtTypeAxis":"us-gaap:ConvertibleDebtMember"},"factValues":[{"value":"8000000","decimals":0}]},{"name":"rpt:f-528","factDimensions":{"xbrl:concept":"us-gaap:DebtConversionConvertedInstrumentWarrantsOrOptionsIssued1","xbrl:period":"2024-01-01T00:00:00/2024-04-01T00:00:00","xbrl:entity":"cik:0001771706","xbrl:unit":"xbrla:shares","us-gaap:LongtermDebtTypeAxis":"us-gaap:ConvertibleDebtMember"},"factValues":[{"value":"6250000"}]},{"name":"rpt:f-529","factDimensions":{"xbrl:concept":"us-gaap:WarrantsAndRightsOutstandingTerm","xbrl:period":"2024-04-01T00:00:00","xbrl:entity":"cik:0001771706","us-gaap:LongtermDebtTypeAxis":"us-gaap:ConvertibleDebtMember"},"factValues":[{"value":"P5Y"}]},{"name":"rpt:f-530","factDimensions":{"xbrl:concept":"us-gaap:DebtInstrumentConvertibleConversionPrice1","xbrl:period":"2024-04-01T00:00:00","xbrl:entity":"cik:0001771706","xbrl:unit":"iso4217:USD/xbrla:shares","us-gaap:LongtermDebtTypeAxis":"us-gaap:ConvertibleDebtMember"},"factValues":[{"value":"0.145","decimals":3}]},{"name":"rpt:f-531","factDimensions":{"xbrl:concept":"us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued","xbrl:period":"2024-01-01T00:00:00/2024-04-01T00:00:00","xbrl:entity":"cik:0001771706","xbrl:unit":"iso4217:USD","us-gaap:LongtermDebtTypeAxis":"us-gaap:ConvertibleDebtMember"},"factValues":[{"value":"497055","decimals":0}]},{"name":"rpt:f-532","factDimensions":{"xbrl:concept":"gdnsf:DebtInstrumentsAdditionalThirdPartyLegalFees","xbrl:period":"2024-01-01T00:00:00/2024-04-01T00:00:00","xbrl:entity":"cik:0001771706","xbrl:unit":"iso4217:USD","us-gaap:LongtermDebtTypeAxis":"us-gaap:ConvertibleDebtMember"},"factValues":[{"value":"1346793","decimals":0}]},{"name":"rpt:f-533","factDimensions":{"xbrl:concept":"us-gaap:DeferredFinanceCostsNet","xbrl:period":"2024-04-01T00:00:00","xbrl:entity":"cik:0001771706","xbrl:unit":"iso4217:USD","us-gaap:LongtermDebtTypeAxis":"us-gaap:ConvertibleDebtMember"},"factValues":[{"value":"967587","decimals":0}]},{"name":"rpt:f-534","factDimensions":{"xbrl:concept":"us-gaap:DeferredFinanceCostsNet","xbrl:period":"2024-01-01T00:00:00","xbrl:entity":"cik:0001771706","xbrl:unit":"iso4217:USD","us-gaap:LongtermDebtTypeAxis":"us-gaap:ConvertibleDebtMember"},"factValues":[{"value":"1083697","decimals":0}]},{"name":"rpt:f-535","factDimensions":{"xbrl:concept":"us-gaap:ConvertibleDebtTableTextBlock","xbrl:period":"2024-01-01T00:00:00/2024-04-01T00:00:00","xbrl:entity":"cik:0001771706"},"factValues":[{"value":"
\u00a0\u00a0\u00a0\u00a0 | March\u00a031,\u00a0 | December 31, | ||||
\u00a0\u00a0\u00a0\u00a0 | 2024 | \u00a0\u00a0\u00a0\u00a0 | 2023 | |||
Beginning of year | $ | 9,140,257 | $ | \u2014 | ||
Proceeds | \u00a0 | \u2014 | \u00a0 | 10,000,000 | ||
Deferred financing costs | \u2014 | (1,346,793) | ||||
PIK interest | 153,686 | 223,954 | ||||
Amortization of deferred financing costs | 116,110 | 263,096 | ||||
End of year | $ | 9,410,053 | \u00a0 | 9,140,257 | ||
Less: current portion | \u00a0 | \u2014 | \u00a0 | \u2014 | ||
Total convertible debt | $ | 9,410,053 | $ | 9,140,257 |
"}]},{"name":"rpt:f-536","factDimensions":{"xbrl:concept":"us-gaap:ConvertibleDebt","xbrl:period":"2024-01-01T00:00:00","xbrl:entity":"cik:0001771706","xbrl:unit":"iso4217:USD","us-gaap:LongtermDebtTypeAxis":"us-gaap:ConvertibleDebtMember"},"factValues":[{"value":"9140257","decimals":0}]},{"name":"rpt:f-537","factDimensions":{"xbrl:concept":"us-gaap:ProceedsFromConvertibleDebt","xbrl:period":"2023-01-01T00:00:00/2024-01-01T00:00:00","xbrl:entity":"cik:0001771706","xbrl:unit":"iso4217:USD","us-gaap:LongtermDebtTypeAxis":"us-gaap:ConvertibleDebtMember"},"factValues":[{"value":"10000000","decimals":0}]},{"name":"rpt:f-538","factDimensions":{"xbrl:concept":"us-gaap:PaymentsOfFinancingCosts","xbrl:period":"2023-01-01T00:00:00/2024-01-01T00:00:00","xbrl:entity":"cik:0001771706","xbrl:unit":"iso4217:USD","us-gaap:LongtermDebtTypeAxis":"us-gaap:ConvertibleDebtMember"},"factValues":[{"value":"1346793","decimals":0}]},{"name":"rpt:f-539","factDimensions":{"xbrl:concept":"us-gaap:PaidInKindInterest","xbrl:period":"2024-01-01T00:00:00/2024-04-01T00:00:00","xbrl:entity":"cik:0001771706","xbrl:unit":"iso4217:USD","us-gaap:LongtermDebtTypeAxis":"us-gaap:ConvertibleDebtMember"},"factValues":[{"value":"153686","decimals":0}]},{"name":"rpt:f-540","factDimensions":{"xbrl:concept":"us-gaap:PaidInKindInterest","xbrl:period":"2023-01-01T00:00:00/2024-01-01T00:00:00","xbrl:entity":"cik:0001771706","xbrl:unit":"iso4217:USD","us-gaap:LongtermDebtTypeAxis":"us-gaap:ConvertibleDebtMember"},"factValues":[{"value":"223954","decimals":0}]},{"name":"rpt:f-541","factDimensions":{"xbrl:concept":"us-gaap:AmortizationOfFinancingCosts","xbrl:period":"2024-01-01T00:00:00/2024-04-01T00:00:00","xbrl:entity":"cik:0001771706","xbrl:unit":"iso4217:USD","us-gaap:LongtermDebtTypeAxis":"us-gaap:ConvertibleDebtMember"},"factValues":[{"value":"116110","decimals":0}]},{"name":"rpt:f-542","factDimensions":{"xbrl:concept":"us-gaap:AmortizationOfFinancingCosts","xbrl:period":"2023-01-01T00:00:00/2024-01-01T00:00:00","xbrl:entity":"cik:0001771706","xbrl:unit":"iso4217:USD","us-gaap:LongtermDebtTypeAxis":"us-gaap:ConvertibleDebtMember"},"factValues":[{"value":"263096","decimals":0}]},{"name":"rpt:f-543","factDimensions":{"xbrl:concept":"us-gaap:ConvertibleDebt","xbrl:period":"2024-04-01T00:00:00","xbrl:entity":"cik:0001771706","xbrl:unit":"iso4217:USD","us-gaap:LongtermDebtTypeAxis":"us-gaap:ConvertibleDebtMember"},"factValues":[{"value":"9410053","decimals":0}]},{"name":"rpt:f-544","factDimensions":{"xbrl:concept":"us-gaap:ConvertibleDebt","xbrl:period":"2024-01-01T00:00:00","xbrl:entity":"cik:0001771706","xbrl:unit":"iso4217:USD","us-gaap:LongtermDebtTypeAxis":"us-gaap:ConvertibleDebtMember"},"factValues":[{"value":"9140257","decimals":0}]},{"name":"rpt:f-545","factDimensions":{"xbrl:concept":"us-gaap:ConvertibleDebtNoncurrent","xbrl:period":"2024-04-01T00:00:00","xbrl:entity":"cik:0001771706","xbrl:unit":"iso4217:USD","us-gaap:LongtermDebtTypeAxis":"us-gaap:ConvertibleDebtMember"},"factValues":[{"value":"9410053","decimals":0}]},{"name":"rpt:f-546","factDimensions":{"xbrl:concept":"us-gaap:ConvertibleDebtNoncurrent","xbrl:period":"2024-01-01T00:00:00","xbrl:entity":"cik:0001771706","xbrl:unit":"iso4217:USD","us-gaap:LongtermDebtTypeAxis":"us-gaap:ConvertibleDebtMember"},"factValues":[{"value":"9140257","decimals":0}]},{"name":"rpt:f-547","factDimensions":{"xbrl:concept":"us-gaap:StockholdersEquityNoteDisclosureTextBlock","xbrl:period":"2024-01-01T00:00:00/2024-04-01T00:00:00","xbrl:entity":"cik:0001771706"},"factValues":[{"value":"
15. Stockholders\u2019 Equity
Shares
The Company\u2019s certificate of incorporation authorized the Company to issue the following classes of shares with the following par value and voting rights as of March 31, 2024. The liquidation and dividend rights are identical among shares equally in the Company\u2019s earnings and losses on an as converted basis.
\u00a0\u00a0\u00a0\u00a0 | Par\u00a0Value | \u00a0\u00a0\u00a0\u00a0 | Authorized | \u00a0\u00a0\u00a0\u00a0 | Voting\u00a0Rights | |
Subordinate Voting Share (\u201cSVS\u201d) | \u00a0 | \u2014 | \u00a0 | Unlimited | \u00a0 | 1 vote for each share |
Multiple Voting Share (\u201cMVS\u201d) | \u00a0 | \u2014 | \u00a0 | Unlimited | \u00a0 | 100 votes for each share |
Super Voting Share | \u00a0 | \u2014 | \u00a0 | Unlimited | \u00a0 | 1,000 votes for each share |
Subordinate Voting Shares
Holders of Subordinate Voting Shares are entitled to one vote in respect of each Subordinate Voting Share held.
Multiple Voting Shares
Holders of Multiple Voting Shares are entitled to votes for each Multiple Voting Share held.
Multiple Voting Shares each have the restricted right to convert to Subordinate Voting Shares subject to adjustments for certain customary corporate changes.
Super Voting Shares
Holders of Super Voting Shares are entitled to votes per Super Voting Share. Each Super Voting share is convertible into one Multiple Voting Share.
Shares Issued
During the three months ended March 31, 2024,\u00a010,342\u00a0Multiple Voting Shares were redeemed for\u00a01,034,200\u00a0Subordinate Voting Shares.
"}]},{"name":"rpt:f-548","factDimensions":{"xbrl:concept":"us-gaap:ScheduleOfStockByClassTextBlock","xbrl:period":"2024-01-01T00:00:00/2024-04-01T00:00:00","xbrl:entity":"cik:0001771706"},"factValues":[{"value":"\u00a0\u00a0\u00a0\u00a0 | Par\u00a0Value | \u00a0\u00a0\u00a0\u00a0 | Authorized | \u00a0\u00a0\u00a0\u00a0 | Voting\u00a0Rights | |
Subordinate Voting Share (\u201cSVS\u201d) | \u00a0 | \u2014 | \u00a0 | Unlimited | \u00a0 | 1 vote for each share |
Multiple Voting Share (\u201cMVS\u201d) | \u00a0 | \u2014 | \u00a0 | Unlimited | \u00a0 | 100 votes for each share |
Super Voting Share | \u00a0 | \u2014 | \u00a0 | Unlimited | \u00a0 | 1,000 votes for each share |
"}]},{"name":"rpt:f-549","factDimensions":{"xbrl:concept":"us-gaap:CommonStockNoParValue","xbrl:period":"2024-04-01T00:00:00","xbrl:entity":"cik:0001771706","xbrl:unit":"iso4217:USD/xbrla:shares","us-gaap:StatementClassOfStockAxis":"gdnsf:SubordinateVotingSharesMember"},"factValues":[{"value":"0"}]},{"name":"rpt:f-550","factDimensions":{"xbrl:concept":"us-gaap:CommonStockSharesAuthorizedUnlimited","xbrl:period":"2024-01-01T00:00:00/2024-04-01T00:00:00","xbrl:entity":"cik:0001771706","us-gaap:StatementClassOfStockAxis":"gdnsf:SubordinateVotingSharesMember"},"factValues":[{"value":"Unlimited"}]},{"name":"rpt:f-551","factDimensions":{"xbrl:concept":"us-gaap:CommonStockVotingRights","xbrl:period":"2024-01-01T00:00:00/2024-04-01T00:00:00","xbrl:entity":"cik:0001771706","us-gaap:StatementClassOfStockAxis":"gdnsf:SubordinateVotingSharesMember"},"factValues":[{"value":"1 vote for each share"}]},{"name":"rpt:f-552","factDimensions":{"xbrl:concept":"gdnsf:CommonStockVotingRightsVotesPerShare","xbrl:period":"2024-04-01T00:00:00","xbrl:entity":"cik:0001771706","xbrl:unit":"gdnsf:Vote","us-gaap:StatementClassOfStockAxis":"gdnsf:SubordinateVotingSharesMember"},"factValues":[{"value":"1"}]},{"name":"rpt:f-553","factDimensions":{"xbrl:concept":"us-gaap:CommonStockNoParValue","xbrl:period":"2024-04-01T00:00:00","xbrl:entity":"cik:0001771706","xbrl:unit":"iso4217:USD/xbrla:shares","us-gaap:StatementClassOfStockAxis":"gdnsf:MultipleVotingSharesMember"},"factValues":[{"value":"0"}]},{"name":"rpt:f-554","factDimensions":{"xbrl:concept":"us-gaap:CommonStockSharesAuthorizedUnlimited","xbrl:period":"2024-01-01T00:00:00/2024-04-01T00:00:00","xbrl:entity":"cik:0001771706","us-gaap:StatementClassOfStockAxis":"gdnsf:MultipleVotingSharesMember"},"factValues":[{"value":"Unlimited"}]},{"name":"rpt:f-555","factDimensions":{"xbrl:concept":"us-gaap:CommonStockVotingRights","xbrl:period":"2024-01-01T00:00:00/2024-04-01T00:00:00","xbrl:entity":"cik:0001771706","us-gaap:StatementClassOfStockAxis":"gdnsf:MultipleVotingSharesMember"},"factValues":[{"value":"100 votes for each share"}]},{"name":"rpt:f-556","factDimensions":{"xbrl:concept":"gdnsf:CommonStockVotingRightsVotesPerShare","xbrl:period":"2024-04-01T00:00:00","xbrl:entity":"cik:0001771706","xbrl:unit":"gdnsf:Vote","us-gaap:StatementClassOfStockAxis":"gdnsf:MultipleVotingSharesMember"},"factValues":[{"value":"100"}]},{"name":"rpt:f-557","factDimensions":{"xbrl:concept":"us-gaap:CommonStockNoParValue","xbrl:period":"2024-04-01T00:00:00","xbrl:entity":"cik:0001771706","xbrl:unit":"iso4217:USD/xbrla:shares","us-gaap:StatementClassOfStockAxis":"gdnsf:SuperVotingSharesMember"},"factValues":[{"value":"0"}]},{"name":"rpt:f-558","factDimensions":{"xbrl:concept":"us-gaap:CommonStockSharesAuthorizedUnlimited","xbrl:period":"2024-01-01T00:00:00/2024-04-01T00:00:00","xbrl:entity":"cik:0001771706","us-gaap:StatementClassOfStockAxis":"gdnsf:SuperVotingSharesMember"},"factValues":[{"value":"Unlimited"}]},{"name":"rpt:f-559","factDimensions":{"xbrl:concept":"us-gaap:CommonStockVotingRights","xbrl:period":"2024-01-01T00:00:00/2024-04-01T00:00:00","xbrl:entity":"cik:0001771706","us-gaap:StatementClassOfStockAxis":"gdnsf:SuperVotingSharesMember"},"factValues":[{"value":"1,000 votes for each share"}]},{"name":"rpt:f-560","factDimensions":{"xbrl:concept":"gdnsf:CommonStockVotingRightsVotesPerShare","xbrl:period":"2024-04-01T00:00:00","xbrl:entity":"cik:0001771706","xbrl:unit":"gdnsf:Vote","us-gaap:StatementClassOfStockAxis":"gdnsf:SuperVotingSharesMember"},"factValues":[{"value":"1000"}]},{"name":"rpt:f-561","factDimensions":{"xbrl:concept":"gdnsf:CommonStockVotingRightsVotesPerShare","xbrl:period":"2024-04-01T00:00:00","xbrl:entity":"cik:0001771706","xbrl:unit":"gdnsf:Vote","us-gaap:StatementClassOfStockAxis":"gdnsf:SubordinateVotingSharesMember"},"factValues":[{"value":"1"}]},{"name":"rpt:f-562","factDimensions":{"xbrl:concept":"gdnsf:CommonStockConvertibleNumberOfShares","xbrl:period":"2024-04-01T00:00:00","xbrl:entity":"cik:0001771706","xbrl:unit":"xbrla:shares","us-gaap:StatementClassOfStockAxis":"gdnsf:SuperVotingSharesMember"},"factValues":[{"value":"1"}]},{"name":"rpt:f-563","factDimensions":{"xbrl:concept":"gdnsf:NumberOfSharesRedeemed","xbrl:period":"2024-01-01T00:00:00/2024-04-01T00:00:00","xbrl:entity":"cik:0001771706","xbrl:unit":"xbrla:shares","us-gaap:StatementClassOfStockAxis":"gdnsf:MultipleVotingSharesMember"},"factValues":[{"value":"10342"}]},{"name":"rpt:f-564","factDimensions":{"xbrl:concept":"gdnsf:NumberOfRedeemedShares","xbrl:period":"2024-01-01T00:00:00/2024-04-01T00:00:00","xbrl:entity":"cik:0001771706","xbrl:unit":"xbrla:shares","us-gaap:StatementClassOfStockAxis":"gdnsf:MultipleVotingSharesMember"},"factValues":[{"value":"1034200"}]},{"name":"rpt:f-565","factDimensions":{"xbrl:concept":"us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock","xbrl:period":"2024-01-01T00:00:00/2024-04-01T00:00:00","xbrl:entity":"cik:0001771706"},"factValues":[{"value":"
16. Stock-Based Compensation
Stock Options
In January\u00a02019, the Company adopted the 2019 Equity Incentive Plan under which the Company may grant incentive stock option, restricted shares, restricted share units, or other awards. Under the terms of the plan, a total of ten\u00a0percent of the number of shares outstanding assuming conversion of all super voting shares and multiple voting shares to subordinate voting shares are permitted to be issued. The exercise price for incentive stock options issued under the plan will be set by the committee but will not be less 100% of the fair market value of the Company\u2019s shares on the date of grant. Incentive stock options have a maximum term of 10 years from the date of grant. The incentive stock options vest at the discretion of the Board of Directors.
Options granted under the equity incentive plan were valued using the Black-Scholes option pricing model with the following weighted average assumptions:
\u00a0\u00a0\u00a0\u00a0 | March\u00a031,\u00a0 | March\u00a031,\u00a0 | \u00a0 | ||
\u00a0\u00a0\u00a0\u00a0 | 2024 | \u00a0\u00a0\u00a0\u00a0 | 2023 | \u00a0 | |
Risk-Free Interest Rate | N/A | 3.84 | % | ||
Weighted Average Exercise Price | N/A | $ | 0.28 | ||
Weighted Average Stock Price | N/A | $ | 0.17 | ||
Expected Life of Options (years) | N/A | 5.85 | |||
Expected Annualized Volatility | N/A | % | 100.00 | % | |
Grant Fair Value | N/A | $ | 0.13 | ||
Expected Forfeiture Rate | N/A | \u00a0 | N/A | ||
Expected Dividend Yield | N/A | \u00a0 | N/A |
Stock option activity for the three months ended March 31, 2024, and for the year ended December 31, 2023, is presented below:
\u00a0\u00a0\u00a0\u00a0 | \u00a0\u00a0\u00a0\u00a0 | Weighted\u00a0Average\u00a0\u00a0 | \u00a0\u00a0\u00a0\u00a0 | Weighted\u00a0Avg.\u00a0 | |||
Number\u00a0of\u00a0Options | Exercise\u00a0Price | Remaining\u00a0Life | |||||
Balance, December 31, 2022 | \u00a0 | 23,547,558 | $ | 0.66 | \u00a0 | 7.30 | |
Forfeitures | \u00a0 | (4,137,079) | \u00a0 | 0.82 | \u00a0 | \u2014 | |
Granted | \u00a0 | 10,558,845 | \u00a0 | 0.25 | \u00a0 | 6.42 | |
Balance, December 31, 2023 | \u00a0 | 29,969,324 | $ | 0.50 | \u00a0 | 6.18 | |
Forfeitures | \u00a0 | (23,813) | \u00a0 | 1.19 | \u00a0 | \u2014 | |
Options Outstanding at March\u00a031,\u00a02024 | \u00a0 | 29,945,511 | $ | 0.50 | \u00a0 | 5.93 | |
Options Exercisable at March\u00a031,\u00a02024 | \u00a0 | 24,596,552 | $ | 0.42 | \u00a0 | 5.53 |
During the three month periods ended March 31, 2024 and 2023, the Company recognized $86,732\u00a0and $1,399,258\u00a0in stock-based compensation relating to stock options, respectively. As of March 31, 2024, the total unrecognized compensation costs related to unvested stock options awards granted was $416,563. In addition, the weighted average period over which the unrecognized compensation expense is expected to be recognized is approximately\u00a01.7\u00a0years. The total intrinsic value of stock options outstanding and exercisable as of March 31, 2024, was $3,388,310 and $2,973,949, respectively.
The Company does not estimate forfeiture rates when calculating compensation expense. The Company records forfeitures as they occur.
Warrants
Subordinate Voting Share (SVS) warrants entitle the holder to purchase one subordinate voting share of the Company. Multiple Voting Share (MVS) warrants entitle the holder to purchase one multiple voting share of the Company.
A summary of the warrants outstanding is as follows:
\u00a0\u00a0\u00a0\u00a0 | Number\u00a0of\u00a0 | \u00a0\u00a0\u00a0\u00a0 | Weighted\u00a0Average\u00a0 | \u00a0\u00a0\u00a0\u00a0 | Weighted\u00a0Average\u00a0 | ||
SVS Warrants | Warrants | Exercise\u00a0Price | Remaining\u00a0Life | ||||
Warrants outstanding at December 31, 2022 | \u00a0 | 150,000 | $ | 1.49 | 2.00 | ||
Granted | \u00a0 | 16,250,000 | 0.20 | 5.00 | |||
Warrants outstanding at December 31, 2023 | 16,400,000 | $ | 0.21 | \u00a0 | 4.57 | ||
Granted | \u2014 | \u2014 | \u2014 | ||||
Warrants outstanding at March 31, 2024 | \u00a0 | 16,400,000 | $ | 0.21 | \u00a0 | 4.32 | |
Warrants exercisable at March 31, 2024 | \u00a0 | 16,400,000 | $ | 0.21 | \u00a0 | 4.32 |
\u00a0\u00a0\u00a0\u00a0 | Number\u00a0of\u00a0 | \u00a0\u00a0\u00a0\u00a0 | Weighted\u00a0Average\u00a0 | \u00a0\u00a0\u00a0\u00a0 | Weighted\u00a0Average\u00a0 | ||
SVS Warrants Denominated in C$ | Warrants | Exercise\u00a0Price | Remaining\u00a0Life | ||||
Warrants outstanding at December 31, 2022 | \u00a0 | 3,037,649 | $ | 3.50 | \u00a0 | 3.23 | |
Granted | \u00a0 | \u2014 | \u00a0 | \u2014 | \u00a0 | \u2014 | |
Warrants outstanding at December 31, 2023 | \u00a0 | 3,037,649 | $ | 3.50 | \u00a0 | 2.23 | |
Granted | \u2014 | \u2014 | \u2014 | ||||
Warrants outstanding at March 31, 2024 | 3,037,649 | $ | 3.50 | 1.98 | |||
Warrants exercisable at March\u00a031,\u00a02024 | \u00a0 | 3,037,649 | $ | 3.50 | \u00a0 | 1.98 |
During the three months ended March 31, 2024, and 2023, $0 in stock-based compensation expense was recorded in connection with outstanding warrants.
Restricted Stock Units (\u201cRSUs\u201d)
The expense associated with RSUs is based on the closing share price of the Company\u2019s subordinate voting shares on the business day immediately preceding the grant date, adjusted for the absence of future dividends and is amortized on a straight-line basis over the periods during which the restrictions lapse. The Company currently has RSUs that vest over a three year period. The awards are generally subject to forfeiture in the event of termination of employment. During the three months ended March 31, 2024, the Company recognized $93,057 and $276,336, respectively, in stock-based compensation expense related to RSUs.
A summary of RSUs is as follows:
\u00a0\u00a0\u00a0\u00a0 | \u00a0\u00a0\u00a0\u00a0 | Weighted Avg. | |||
Number\u00a0of\u00a0Shares | Fair Value | ||||
Balance, December 31, 2022 | \u00a0 | 3,221,677 | $ | 0.81 | |
Forfeitures | (678,666) | 0.54 | |||
Balance, December 31, 2023 and March 31, 2024 | 2,543,011 | 0.88 | |||
Vested at March 31, 2024 | 1,025,253 | $ | 0.95 |
"}]},{"name":"rpt:f-566","factDimensions":{"xbrl:concept":"us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum","xbrl:period":"2024-01-01T00:00:00/2024-04-01T00:00:00","xbrl:entity":"cik:0001771706","us-gaap:AwardTypeAxis":"us-gaap:EmployeeStockOptionMember"},"factValues":[{"value":"0.10"}]},{"name":"rpt:f-567","factDimensions":{"xbrl:concept":"gdnsf:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisePriceMinimumPercentageOfGrantDateFairMarketValueOfShares","xbrl:period":"2024-04-01T00:00:00","xbrl:entity":"cik:0001771706","us-gaap:AwardTypeAxis":"us-gaap:EmployeeStockOptionMember"},"factValues":[{"value":"1","decimals":2}]},{"name":"rpt:f-568","factDimensions":{"xbrl:concept":"us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod","xbrl:period":"2024-01-01T00:00:00/2024-04-01T00:00:00","xbrl:entity":"cik:0001771706","srt:RangeAxis":"srt:MaximumMember","us-gaap:AwardTypeAxis":"us-gaap:EmployeeStockOptionMember"},"factValues":[{"value":"P10Y"}]},{"name":"rpt:f-569","factDimensions":{"xbrl:concept":"us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock","xbrl:period":"2024-01-01T00:00:00/2024-04-01T00:00:00","xbrl:entity":"cik:0001771706"},"factValues":[{"value":"
\u00a0\u00a0\u00a0\u00a0 | March\u00a031,\u00a0 | March\u00a031,\u00a0 | \u00a0 | ||
\u00a0\u00a0\u00a0\u00a0 | 2024 | \u00a0\u00a0\u00a0\u00a0 | 2023 | \u00a0 | |
Risk-Free Interest Rate | N/A | 3.84 | % | ||
Weighted Average Exercise Price | N/A | $ | 0.28 | ||
Weighted Average Stock Price | N/A | $ | 0.17 | ||
Expected Life of Options (years) | N/A | 5.85 | |||
Expected Annualized Volatility | N/A | % | 100.00 | % | |
Grant Fair Value | N/A | $ | 0.13 | ||
Expected Forfeiture Rate | N/A | \u00a0 | N/A | ||
Expected Dividend Yield | N/A | \u00a0 | N/A |
\u00a0\u00a0\u00a0\u00a0 | \u00a0\u00a0\u00a0\u00a0 | Weighted\u00a0Average\u00a0\u00a0 | \u00a0\u00a0\u00a0\u00a0 | Weighted\u00a0Avg.\u00a0 | |||
Number\u00a0of\u00a0Options | Exercise\u00a0Price | Remaining\u00a0Life | |||||
Balance, December 31, 2022 | \u00a0 | 23,547,558 | $ | 0.66 | \u00a0 | 7.30 | |
Forfeitures | \u00a0 | (4,137,079) | \u00a0 | 0.82 | \u00a0 | \u2014 | |
Granted | \u00a0 | 10,558,845 | \u00a0 | 0.25 | \u00a0 | 6.42 | |
Balance, December 31, 2023 | \u00a0 | 29,969,324 | $ | 0.50 | \u00a0 | 6.18 | |
Forfeitures | \u00a0 | (23,813) | \u00a0 | 1.19 | \u00a0 | \u2014 | |
Options Outstanding at March\u00a031,\u00a02024 | \u00a0 | 29,945,511 | $ | 0.50 | \u00a0 | 5.93 | |
Options Exercisable at March\u00a031,\u00a02024 | \u00a0 | 24,596,552 | $ | 0.42 | \u00a0 | 5.53 |
\u00a0\u00a0\u00a0\u00a0 | Number\u00a0of\u00a0 | \u00a0\u00a0\u00a0\u00a0 | Weighted\u00a0Average\u00a0 | \u00a0\u00a0\u00a0\u00a0 | Weighted\u00a0Average\u00a0 | ||
SVS Warrants | Warrants | Exercise\u00a0Price | Remaining\u00a0Life | ||||
Warrants outstanding at December 31, 2022 | \u00a0 | 150,000 | $ | 1.49 | 2.00 | ||
Granted | \u00a0 | 16,250,000 | 0.20 | 5.00 | |||
Warrants outstanding at December 31, 2023 | 16,400,000 | $ | 0.21 | \u00a0 | 4.57 | ||
Granted | \u2014 | \u2014 | \u2014 | ||||
Warrants outstanding at March 31, 2024 | \u00a0 | 16,400,000 | $ | 0.21 | \u00a0 | 4.32 | |
Warrants exercisable at March 31, 2024 | \u00a0 | 16,400,000 | $ | 0.21 | \u00a0 | 4.32 |
\u00a0\u00a0\u00a0\u00a0 | Number\u00a0of\u00a0 | \u00a0\u00a0\u00a0\u00a0 | Weighted\u00a0Average\u00a0 | \u00a0\u00a0\u00a0\u00a0 | Weighted\u00a0Average\u00a0 | ||
SVS Warrants Denominated in C$ | Warrants | Exercise\u00a0Price | Remaining\u00a0Life | ||||
Warrants outstanding at December 31, 2022 | \u00a0 | 3,037,649 | $ | 3.50 | \u00a0 | 3.23 | |
Granted | \u00a0 | \u2014 | \u00a0 | \u2014 | \u00a0 | \u2014 | |
Warrants outstanding at December 31, 2023 | \u00a0 | 3,037,649 | $ | 3.50 | \u00a0 | 2.23 | |
Granted | \u2014 | \u2014 | \u2014 | ||||
Warrants outstanding at March 31, 2024 | 3,037,649 | $ | 3.50 | 1.98 | |||
Warrants exercisable at March\u00a031,\u00a02024 | \u00a0 | 3,037,649 | $ | 3.50 | \u00a0 | 1.98 |
"}]},{"name":"rpt:f-605","factDimensions":{"xbrl:concept":"us-gaap:ClassOfWarrantOrRightOutstanding","xbrl:period":"2023-01-01T00:00:00","xbrl:entity":"cik:0001771706","xbrl:unit":"xbrla:shares","us-gaap:ClassOfWarrantOrRightAxis":"gdnsf:CommonStockWarrantsEquitySubordinateVotingShareWarrantsDenominatedInUnitedStatesDollarsMember"},"factValues":[{"value":"150000"}]},{"name":"rpt:f-606","factDimensions":{"xbrl:concept":"gdnsf:ClassOfWarrantOrRightOutstandingWeightedAverageExercisePrice","xbrl:period":"2023-01-01T00:00:00","xbrl:entity":"cik:0001771706","xbrl:unit":"iso4217:USD/xbrla:shares","us-gaap:ClassOfWarrantOrRightAxis":"gdnsf:CommonStockWarrantsEquitySubordinateVotingShareWarrantsDenominatedInUnitedStatesDollarsMember"},"factValues":[{"value":"1.49","decimals":2}]},{"name":"rpt:f-607","factDimensions":{"xbrl:concept":"gdnsf:ClassOfWarrantOrRightOutstandingWeightedAverageRemainingContractualTerm","xbrl:period":"2022-01-01T00:00:00/2023-01-01T00:00:00","xbrl:entity":"cik:0001771706","us-gaap:ClassOfWarrantOrRightAxis":"gdnsf:CommonStockWarrantsEquitySubordinateVotingShareWarrantsDenominatedInUnitedStatesDollarsMember"},"factValues":[{"value":"P2Y"}]},{"name":"rpt:f-608","factDimensions":{"xbrl:concept":"gdnsf:ClassOfWarrantOrRightGranted","xbrl:period":"2023-01-01T00:00:00/2024-01-01T00:00:00","xbrl:entity":"cik:0001771706","xbrl:unit":"xbrla:shares","us-gaap:ClassOfWarrantOrRightAxis":"gdnsf:CommonStockWarrantsEquitySubordinateVotingShareWarrantsDenominatedInUnitedStatesDollarsMember"},"factValues":[{"value":"16250000"}]},{"name":"rpt:f-609","factDimensions":{"xbrl:concept":"gdnsf:ClassOfWarrantOrRightGrantedWeightedAverageExercisePrice","xbrl:period":"2023-01-01T00:00:00/2024-01-01T00:00:00","xbrl:entity":"cik:0001771706","xbrl:unit":"iso4217:USD/xbrla:shares","us-gaap:ClassOfWarrantOrRightAxis":"gdnsf:CommonStockWarrantsEquitySubordinateVotingShareWarrantsDenominatedInUnitedStatesDollarsMember"},"factValues":[{"value":"0.20","decimals":2}]},{"name":"rpt:f-610","factDimensions":{"xbrl:concept":"gdnsf:ClassOfWarrantOrRightGrantedWeightedAverageRemainingContractualTerm","xbrl:period":"2023-01-01T00:00:00/2024-01-01T00:00:00","xbrl:entity":"cik:0001771706","us-gaap:ClassOfWarrantOrRightAxis":"gdnsf:CommonStockWarrantsEquitySubordinateVotingShareWarrantsDenominatedInUnitedStatesDollarsMember"},"factValues":[{"value":"P5Y"}]},{"name":"rpt:f-611","factDimensions":{"xbrl:concept":"us-gaap:ClassOfWarrantOrRightOutstanding","xbrl:period":"2024-01-01T00:00:00","xbrl:entity":"cik:0001771706","xbrl:unit":"xbrla:shares","us-gaap:ClassOfWarrantOrRightAxis":"gdnsf:CommonStockWarrantsEquitySubordinateVotingShareWarrantsDenominatedInUnitedStatesDollarsMember"},"factValues":[{"value":"16400000"}]},{"name":"rpt:f-612","factDimensions":{"xbrl:concept":"gdnsf:ClassOfWarrantOrRightOutstandingWeightedAverageExercisePrice","xbrl:period":"2024-01-01T00:00:00","xbrl:entity":"cik:0001771706","xbrl:unit":"iso4217:USD/xbrla:shares","us-gaap:ClassOfWarrantOrRightAxis":"gdnsf:CommonStockWarrantsEquitySubordinateVotingShareWarrantsDenominatedInUnitedStatesDollarsMember"},"factValues":[{"value":"0.21","decimals":2}]},{"name":"rpt:f-613","factDimensions":{"xbrl:concept":"gdnsf:ClassOfWarrantOrRightOutstandingWeightedAverageRemainingContractualTerm","xbrl:period":"2023-01-01T00:00:00/2024-01-01T00:00:00","xbrl:entity":"cik:0001771706","us-gaap:ClassOfWarrantOrRightAxis":"gdnsf:CommonStockWarrantsEquitySubordinateVotingShareWarrantsDenominatedInUnitedStatesDollarsMember"},"factValues":[{"value":"P4Y6M25D"}]},{"name":"rpt:f-614","factDimensions":{"xbrl:concept":"us-gaap:ClassOfWarrantOrRightOutstanding","xbrl:period":"2024-04-01T00:00:00","xbrl:entity":"cik:0001771706","xbrl:unit":"xbrla:shares","us-gaap:ClassOfWarrantOrRightAxis":"gdnsf:CommonStockWarrantsEquitySubordinateVotingShareWarrantsDenominatedInUnitedStatesDollarsMember"},"factValues":[{"value":"16400000"}]},{"name":"rpt:f-615","factDimensions":{"xbrl:concept":"gdnsf:ClassOfWarrantOrRightOutstandingWeightedAverageExercisePrice","xbrl:period":"2024-04-01T00:00:00","xbrl:entity":"cik:0001771706","xbrl:unit":"iso4217:USD/xbrla:shares","us-gaap:ClassOfWarrantOrRightAxis":"gdnsf:CommonStockWarrantsEquitySubordinateVotingShareWarrantsDenominatedInUnitedStatesDollarsMember"},"factValues":[{"value":"0.21","decimals":2}]},{"name":"rpt:f-616","factDimensions":{"xbrl:concept":"gdnsf:ClassOfWarrantOrRightOutstandingWeightedAverageRemainingContractualTerm","xbrl:period":"2024-01-01T00:00:00/2024-04-01T00:00:00","xbrl:entity":"cik:0001771706","us-gaap:ClassOfWarrantOrRightAxis":"gdnsf:CommonStockWarrantsEquitySubordinateVotingShareWarrantsDenominatedInUnitedStatesDollarsMember"},"factValues":[{"value":"P4Y3M25D"}]},{"name":"rpt:f-617","factDimensions":{"xbrl:concept":"gdnsf:ClassOfWarrantOrRightExercisable","xbrl:period":"2024-04-01T00:00:00","xbrl:entity":"cik:0001771706","xbrl:unit":"xbrla:shares","us-gaap:ClassOfWarrantOrRightAxis":"gdnsf:CommonStockWarrantsEquitySubordinateVotingShareWarrantsDenominatedInUnitedStatesDollarsMember"},"factValues":[{"value":"16400000"}]},{"name":"rpt:f-618","factDimensions":{"xbrl:concept":"gdnsf:ClassOfWarrantOrRightExercisableWeightedAverageExercisePrice","xbrl:period":"2024-04-01T00:00:00","xbrl:entity":"cik:0001771706","xbrl:unit":"iso4217:USD/xbrla:shares","us-gaap:ClassOfWarrantOrRightAxis":"gdnsf:CommonStockWarrantsEquitySubordinateVotingShareWarrantsDenominatedInUnitedStatesDollarsMember"},"factValues":[{"value":"0.21","decimals":2}]},{"name":"rpt:f-619","factDimensions":{"xbrl:concept":"gdnsf:ClassOfWarrantOrRightExercisableWeightedAverageRemainingContractualTerm","xbrl:period":"2024-01-01T00:00:00/2024-04-01T00:00:00","xbrl:entity":"cik:0001771706","us-gaap:ClassOfWarrantOrRightAxis":"gdnsf:CommonStockWarrantsEquitySubordinateVotingShareWarrantsDenominatedInUnitedStatesDollarsMember"},"factValues":[{"value":"P4Y3M25D"}]},{"name":"rpt:f-620","factDimensions":{"xbrl:concept":"us-gaap:ClassOfWarrantOrRightOutstanding","xbrl:period":"2023-01-01T00:00:00","xbrl:entity":"cik:0001771706","xbrl:unit":"xbrla:shares","us-gaap:ClassOfWarrantOrRightAxis":"gdnsf:CommonStockWarrantsEquitySubordinateVotingShareWarrantsDenominatedInCanadianDollarsMember"},"factValues":[{"value":"3037649"}]},{"name":"rpt:f-621","factDimensions":{"xbrl:concept":"gdnsf:ClassOfWarrantOrRightOutstandingWeightedAverageExercisePrice","xbrl:period":"2023-01-01T00:00:00","xbrl:entity":"cik:0001771706","xbrl:unit":"iso4217:USD/xbrla:shares","us-gaap:ClassOfWarrantOrRightAxis":"gdnsf:CommonStockWarrantsEquitySubordinateVotingShareWarrantsDenominatedInCanadianDollarsMember"},"factValues":[{"value":"3.50","decimals":2}]},{"name":"rpt:f-622","factDimensions":{"xbrl:concept":"gdnsf:ClassOfWarrantOrRightOutstandingWeightedAverageRemainingContractualTerm","xbrl:period":"2022-01-01T00:00:00/2023-01-01T00:00:00","xbrl:entity":"cik:0001771706","us-gaap:ClassOfWarrantOrRightAxis":"gdnsf:CommonStockWarrantsEquitySubordinateVotingShareWarrantsDenominatedInCanadianDollarsMember"},"factValues":[{"value":"P3Y2M23D"}]},{"name":"rpt:f-623","factDimensions":{"xbrl:concept":"us-gaap:ClassOfWarrantOrRightOutstanding","xbrl:period":"2024-01-01T00:00:00","xbrl:entity":"cik:0001771706","xbrl:unit":"xbrla:shares","us-gaap:ClassOfWarrantOrRightAxis":"gdnsf:CommonStockWarrantsEquitySubordinateVotingShareWarrantsDenominatedInCanadianDollarsMember"},"factValues":[{"value":"3037649"}]},{"name":"rpt:f-624","factDimensions":{"xbrl:concept":"gdnsf:ClassOfWarrantOrRightOutstandingWeightedAverageExercisePrice","xbrl:period":"2024-01-01T00:00:00","xbrl:entity":"cik:0001771706","xbrl:unit":"iso4217:USD/xbrla:shares","us-gaap:ClassOfWarrantOrRightAxis":"gdnsf:CommonStockWarrantsEquitySubordinateVotingShareWarrantsDenominatedInCanadianDollarsMember"},"factValues":[{"value":"3.50","decimals":2}]},{"name":"rpt:f-625","factDimensions":{"xbrl:concept":"gdnsf:ClassOfWarrantOrRightOutstandingWeightedAverageRemainingContractualTerm","xbrl:period":"2023-01-01T00:00:00/2024-01-01T00:00:00","xbrl:entity":"cik:0001771706","us-gaap:ClassOfWarrantOrRightAxis":"gdnsf:CommonStockWarrantsEquitySubordinateVotingShareWarrantsDenominatedInCanadianDollarsMember"},"factValues":[{"value":"P2Y2M23D"}]},{"name":"rpt:f-626","factDimensions":{"xbrl:concept":"us-gaap:ClassOfWarrantOrRightOutstanding","xbrl:period":"2024-04-01T00:00:00","xbrl:entity":"cik:0001771706","xbrl:unit":"xbrla:shares","us-gaap:ClassOfWarrantOrRightAxis":"gdnsf:CommonStockWarrantsEquitySubordinateVotingShareWarrantsDenominatedInCanadianDollarsMember"},"factValues":[{"value":"3037649"}]},{"name":"rpt:f-627","factDimensions":{"xbrl:concept":"gdnsf:ClassOfWarrantOrRightOutstandingWeightedAverageExercisePrice","xbrl:period":"2024-04-01T00:00:00","xbrl:entity":"cik:0001771706","xbrl:unit":"iso4217:USD/xbrla:shares","us-gaap:ClassOfWarrantOrRightAxis":"gdnsf:CommonStockWarrantsEquitySubordinateVotingShareWarrantsDenominatedInCanadianDollarsMember"},"factValues":[{"value":"3.50","decimals":2}]},{"name":"rpt:f-628","factDimensions":{"xbrl:concept":"gdnsf:ClassOfWarrantOrRightOutstandingWeightedAverageRemainingContractualTerm","xbrl:period":"2024-01-01T00:00:00/2024-04-01T00:00:00","xbrl:entity":"cik:0001771706","us-gaap:ClassOfWarrantOrRightAxis":"gdnsf:CommonStockWarrantsEquitySubordinateVotingShareWarrantsDenominatedInCanadianDollarsMember"},"factValues":[{"value":"P1Y11M23D"}]},{"name":"rpt:f-629","factDimensions":{"xbrl:concept":"gdnsf:ClassOfWarrantOrRightExercisable","xbrl:period":"2024-04-01T00:00:00","xbrl:entity":"cik:0001771706","xbrl:unit":"xbrla:shares","us-gaap:ClassOfWarrantOrRightAxis":"gdnsf:CommonStockWarrantsEquitySubordinateVotingShareWarrantsDenominatedInCanadianDollarsMember"},"factValues":[{"value":"3037649"}]},{"name":"rpt:f-630","factDimensions":{"xbrl:concept":"gdnsf:ClassOfWarrantOrRightExercisableWeightedAverageExercisePrice","xbrl:period":"2024-04-01T00:00:00","xbrl:entity":"cik:0001771706","xbrl:unit":"iso4217:USD/xbrla:shares","us-gaap:ClassOfWarrantOrRightAxis":"gdnsf:CommonStockWarrantsEquitySubordinateVotingShareWarrantsDenominatedInCanadianDollarsMember"},"factValues":[{"value":"3.50","decimals":2}]},{"name":"rpt:f-631","factDimensions":{"xbrl:concept":"gdnsf:ClassOfWarrantOrRightExercisableWeightedAverageRemainingContractualTerm","xbrl:period":"2024-01-01T00:00:00/2024-04-01T00:00:00","xbrl:entity":"cik:0001771706","us-gaap:ClassOfWarrantOrRightAxis":"gdnsf:CommonStockWarrantsEquitySubordinateVotingShareWarrantsDenominatedInCanadianDollarsMember"},"factValues":[{"value":"P1Y11M23D"}]},{"name":"rpt:f-632","factDimensions":{"xbrl:concept":"us-gaap:AllocatedShareBasedCompensationExpense","xbrl:period":"2023-01-01T00:00:00/2023-04-01T00:00:00","xbrl:entity":"cik:0001771706","xbrl:unit":"iso4217:USD","us-gaap:ClassOfWarrantOrRightAxis":"gdnsf:CommonStockWarrantsEquitySubordinateVotingShareWarrantsMember"},"factValues":[{"value":"0","decimals":0}]},{"name":"rpt:f-633","factDimensions":{"xbrl:concept":"us-gaap:AllocatedShareBasedCompensationExpense","xbrl:period":"2024-01-01T00:00:00/2024-04-01T00:00:00","xbrl:entity":"cik:0001771706","xbrl:unit":"iso4217:USD","us-gaap:ClassOfWarrantOrRightAxis":"gdnsf:CommonStockWarrantsEquitySubordinateVotingShareWarrantsMember"},"factValues":[{"value":"0","decimals":0}]},{"name":"rpt:f-634","factDimensions":{"xbrl:concept":"us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1","xbrl:period":"2024-01-01T00:00:00/2024-04-01T00:00:00","xbrl:entity":"cik:0001771706","us-gaap:AwardTypeAxis":"us-gaap:RestrictedStockUnitsRSUMember"},"factValues":[{"value":"P3Y"}]},{"name":"rpt:f-635","factDimensions":{"xbrl:concept":"us-gaap:AllocatedShareBasedCompensationExpense","xbrl:period":"2024-01-01T00:00:00/2024-04-01T00:00:00","xbrl:entity":"cik:0001771706","xbrl:unit":"iso4217:USD","us-gaap:AwardTypeAxis":"us-gaap:RestrictedStockUnitsRSUMember"},"factValues":[{"value":"93057","decimals":0}]},{"name":"rpt:f-636","factDimensions":{"xbrl:concept":"us-gaap:AllocatedShareBasedCompensationExpense","xbrl:period":"2023-01-01T00:00:00/2024-01-01T00:00:00","xbrl:entity":"cik:0001771706","xbrl:unit":"iso4217:USD","us-gaap:AwardTypeAxis":"us-gaap:RestrictedStockUnitsRSUMember"},"factValues":[{"value":"276336","decimals":0}]},{"name":"rpt:f-637","factDimensions":{"xbrl:concept":"us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock","xbrl:period":"2024-01-01T00:00:00/2024-04-01T00:00:00","xbrl:entity":"cik:0001771706"},"factValues":[{"value":"
\u00a0\u00a0\u00a0\u00a0 | \u00a0\u00a0\u00a0\u00a0 | Weighted Avg. | |||
Number\u00a0of\u00a0Shares | Fair Value | ||||
Balance, December 31, 2022 | \u00a0 | 3,221,677 | $ | 0.81 | |
Forfeitures | (678,666) | 0.54 | |||
Balance, December 31, 2023 and March 31, 2024 | 2,543,011 | 0.88 | |||
Vested at March 31, 2024 | 1,025,253 | $ | 0.95 |
"}]},{"name":"rpt:f-638","factDimensions":{"xbrl:concept":"us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber","xbrl:period":"2023-01-01T00:00:00","xbrl:entity":"cik:0001771706","xbrl:unit":"xbrla:shares","us-gaap:AwardTypeAxis":"us-gaap:RestrictedStockUnitsRSUMember"},"factValues":[{"value":"3221677"}]},{"name":"rpt:f-639","factDimensions":{"xbrl:concept":"us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue","xbrl:period":"2023-01-01T00:00:00","xbrl:entity":"cik:0001771706","xbrl:unit":"iso4217:USD/xbrla:shares","us-gaap:AwardTypeAxis":"us-gaap:RestrictedStockUnitsRSUMember"},"factValues":[{"value":"0.81","decimals":2}]},{"name":"rpt:f-640","factDimensions":{"xbrl:concept":"us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod","xbrl:period":"2023-01-01T00:00:00/2024-04-01T00:00:00","xbrl:entity":"cik:0001771706","xbrl:unit":"xbrla:shares","us-gaap:AwardTypeAxis":"gdnsf:AwardsGrantedOnMarch152022Member"},"factValues":[{"value":"678666"}]},{"name":"rpt:f-641","factDimensions":{"xbrl:concept":"us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue","xbrl:period":"2023-01-01T00:00:00/2024-04-01T00:00:00","xbrl:entity":"cik:0001771706","xbrl:unit":"iso4217:USD/xbrla:shares","us-gaap:AwardTypeAxis":"gdnsf:AwardsGrantedOnMarch152022Member"},"factValues":[{"value":"0.54","decimals":2}]},{"name":"rpt:f-642","factDimensions":{"xbrl:concept":"us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber","xbrl:period":"2024-04-01T00:00:00","xbrl:entity":"cik:0001771706","xbrl:unit":"xbrla:shares","us-gaap:AwardTypeAxis":"us-gaap:RestrictedStockUnitsRSUMember"},"factValues":[{"value":"2543011"}]},{"name":"rpt:f-643","factDimensions":{"xbrl:concept":"us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber","xbrl:period":"2024-01-01T00:00:00","xbrl:entity":"cik:0001771706","xbrl:unit":"xbrla:shares","us-gaap:AwardTypeAxis":"us-gaap:RestrictedStockUnitsRSUMember"},"factValues":[{"value":"2543011"}]},{"name":"rpt:f-644","factDimensions":{"xbrl:concept":"us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue","xbrl:period":"2024-04-01T00:00:00","xbrl:entity":"cik:0001771706","xbrl:unit":"iso4217:USD/xbrla:shares","us-gaap:AwardTypeAxis":"us-gaap:RestrictedStockUnitsRSUMember"},"factValues":[{"value":"0.88","decimals":2}]},{"name":"rpt:f-645","factDimensions":{"xbrl:concept":"us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue","xbrl:period":"2024-01-01T00:00:00","xbrl:entity":"cik:0001771706","xbrl:unit":"iso4217:USD/xbrla:shares","us-gaap:AwardTypeAxis":"us-gaap:RestrictedStockUnitsRSUMember"},"factValues":[{"value":"0.88","decimals":2}]},{"name":"rpt:f-646","factDimensions":{"xbrl:concept":"us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod","xbrl:period":"2024-01-01T00:00:00/2024-04-01T00:00:00","xbrl:entity":"cik:0001771706","xbrl:unit":"xbrla:shares","us-gaap:AwardTypeAxis":"us-gaap:RestrictedStockUnitsRSUMember"},"factValues":[{"value":"1025253"}]},{"name":"rpt:f-647","factDimensions":{"xbrl:concept":"us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue","xbrl:period":"2024-01-01T00:00:00/2024-04-01T00:00:00","xbrl:entity":"cik:0001771706","xbrl:unit":"iso4217:USD/xbrla:shares","us-gaap:AwardTypeAxis":"us-gaap:RestrictedStockUnitsRSUMember"},"factValues":[{"value":"0.95","decimals":2}]},{"name":"rpt:f-648","factDimensions":{"xbrl:concept":"us-gaap:CommitmentsAndContingenciesDisclosureTextBlock","xbrl:period":"2024-01-01T00:00:00/2024-04-01T00:00:00","xbrl:entity":"cik:0001771706"},"factValues":[{"value":"
17. Commitments and Contingencies
Legal proceedings
Schneyer
On February\u00a025, 2019, Dr.\u00a0Mark Schneyer (\u201cSchneyer\u201d) filed a lawsuit in Minnesota District Court, Fourth District (the \u201cCourt\u201d), on his own behalf and, derivatively, on behalf of Dorchester Capital, LLC, naming Vireo Health, Inc. (\u201cVireo U.S.\u201d), Dorchester Management, LLC (\u201cDorchester Management\u201d), and Dorchester Capital, LLC (\u201cCapital\u201d), as defendants. The essence of the claims made by Schneyer is Vireo U.S. paid an inadequate price for MaryMed, LLC (\u201cMaryMed\u201d), which it purchased it from Capital in 2018, and that the consideration given\u00a0\u2013 shares of preferred stock in Vireo U.S.\u00a0\u2013 was distributed inappropriately by Capital at the direction of Dorchester Management (the managing member of Capital). Schneyer, who is a Class\u00a0B member of Capital, sought unspecified damages in excess of\u00a0$50,000\u00a0and other relief. Dorchester Management, LLC is an affiliated entity to Vireo U.S. and was previously used as a management company over Dorchester Capital,\u00a0LLC. It no longer has active operations following Vireo Health,\u00a0Inc.\u2019s acquisition of MaryMed, LLC in 2018. It is owned and controlled by Kyle E. Kingsley and Amber H. Shimpa, executive officers and directors of Vireo U.S. and the Company.
While Vireo U.S. continues to believe that Schneyer\u2019s claims lack merit, it agreed to settle the litigation in April 2023 to avoid the expense, distraction and risk of the pre-trial and trial processes. Entering into this settlement in no way changed the defendants\u2019 position that they did nothing wrong and that the claims were baseless.
Verano
On January 31, 2022, the Company entered into the Arrangement Agreement with Verano, pursuant to which Verano was to acquire all of the issued and outstanding shares of Goodness Growth pursuant to a Plan of Arrangement. Subject to the terms and conditions set forth in the Arrangement Agreement and the Plan of Arrangement, holders of Goodness Growth Shares would receive\u00a00.22652\u00a0of a Verano Subordinate Voting Share, subject to adjustment as described below, for each Subordinate Voting Share held, and\u00a022.652\u00a0Verano Subordinate Voting Shares for each Multiple Voting Share and Super Voting Share held, immediately prior to the effective time of the Arrangement.
\u00a0
On October 13, 2022, Goodness Growth received a notice of purported termination of the Arrangement Agreement (the \u201cNotice\u201d) from Verano. The Notice asserted certain breaches of the Arrangement Agreement, including claims the Company\u2019s public filings and communications with respect to its business and ongoing operations were misleading and that the Company breached its representations to Verano under the Arrangement Agreement. Verano also claimed, as a result of such breaches, it is entitled to payment of a $14,875,000\u00a0termination fee and its transaction expenses. Goodness Growth denies all of Verano\u2019s allegations and affirmatively asserts that it has complied with its obligations under the Arrangement Agreement, and with its disclosure obligations under US and Canadian law, in all material respects at all times. The Company believes that Verano has no factual or legal basis to justify or support its purported termination of the Arrangement Agreement, which the Company determined to treat as a repudiation of the Arrangement Agreement.
\u00a0
On October 21, 2022, Goodness Growth commenced an action in the Supreme Court of British Columbia against Verano after Verano wrongfully repudiated the Arrangement Agreement. The Company is seeking damages, costs and interest, based on Verano's breach of contract and of its duty of good faith and honest performance.
\u00a0
On November 14, 2022, Verano filed counterclaims against the Company for the termination fee and transaction expenses described above.
\u00a0
On July 31, 2023, the Company filed a requisition for adjournment of its application filed July 14, 2023, and set for hearing on July 31, 2023 to compel Verano\u2019s compliance with document production based upon the Company\u2019s belief that Verano was engaging in tactics to delay the litigation.\u00a0
\u00a0
Throughout 2023, the Company served\u00a04\u00a0lists of documents, reviewed document production from Verano, and prepared for examinations for discovery.\u00a0 The Company also prepared materials in anticipation of seeking summary determination of its claim, which it anticipates filing within\u00a030 days.
\u00a0
Due to uncertainties inherent in litigation, it is not possible for Goodness Growth to predict the timing or final outcome of the legal proceedings against Verano or to determine the amount of damages, if any, that may be awarded.\u00a0 The damages sought will be significant and material given that Verano\u2019s breach left the Company in a vulnerable position resulting in the Company being constrained in its ability to fund growth initiatives that were desirable and that its competitors were able to undertake, most notably in Minnesota and New York markets.
Lease commitments
The Company leases various facilities, under non-cancelable finance and operating leases, which expire at various dates through September 2041.
"}]},{"name":"rpt:f-649","factDimensions":{"xbrl:concept":"us-gaap:LossContingencyEstimateOfPossibleLoss","xbrl:period":"2019-02-26T00:00:00","xbrl:entity":"cik:0001771706","xbrl:unit":"iso4217:USD","srt:RangeAxis":"srt:MinimumMember","srt:TitleOfIndividualAxis":"gdnsf:Dr.MarkSchneyerMember"},"factValues":[{"value":"50000","decimals":0}]},{"name":"rpt:f-650","factDimensions":{"xbrl:concept":"gdnsf:ExchangeRatioOfSharesReceivable","xbrl:period":"2022-02-01T00:00:00","xbrl:entity":"cik:0001771706","us-gaap:StatementClassOfStockAxis":"gdnsf:SubordinateVotingSharesMember","us-gaap:TypeOfArrangementAxis":"gdnsf:ArrangementAgreementWithVeranoHoldingsCorpMember"},"factValues":[{"value":"0.22652","decimals":5}]},{"name":"rpt:f-651","factDimensions":{"xbrl:concept":"gdnsf:ExchangeRatioOfSharesReceivable","xbrl:period":"2022-02-01T00:00:00","xbrl:entity":"cik:0001771706","us-gaap:StatementClassOfStockAxis":"gdnsf:MultipleVotingSharesMember","us-gaap:TypeOfArrangementAxis":"gdnsf:ArrangementAgreementWithVeranoHoldingsCorpMember"},"factValues":[{"value":"22.652","decimals":3}]},{"name":"rpt:f-652","factDimensions":{"xbrl:concept":"us-gaap:LossContingencyDamagesSoughtValue","xbrl:period":"2022-10-13T00:00:00/2022-10-14T00:00:00","xbrl:entity":"cik:0001771706","xbrl:unit":"iso4217:USD","us-gaap:TypeOfArrangementAxis":"gdnsf:ArrangementAgreementWithVeranoHoldingsCorpMember"},"factValues":[{"value":"14875000","decimals":0}]},{"name":"rpt:f-653","factDimensions":{"xbrl:concept":"gdnsf:LossContingencyListOfDocumentsServedForExaminationNumber","xbrl:period":"2023-01-01T00:00:00/2024-01-01T00:00:00","xbrl:entity":"cik:0001771706","xbrl:unit":"gdnsf:item","us-gaap:TypeOfArrangementAxis":"gdnsf:ArrangementAgreementWithVeranoHoldingsCorpMember"},"factValues":[{"value":"4"}]},{"name":"rpt:f-654","factDimensions":{"xbrl:concept":"gdnsf:LossContingencyMaterialsSubmissionForClaimsFilingPeriod","xbrl:period":"2023-01-01T00:00:00/2024-01-01T00:00:00","xbrl:entity":"cik:0001771706","us-gaap:TypeOfArrangementAxis":"gdnsf:ArrangementAgreementWithVeranoHoldingsCorpMember"},"factValues":[{"value":"P30D"}]},{"name":"rpt:f-655","factDimensions":{"xbrl:concept":"gdnsf:GeneralAndAdministrativeExpensesTextBlock","xbrl:period":"2024-01-01T00:00:00/2024-04-01T00:00:00","xbrl:entity":"cik:0001771706"},"factValues":[{"value":"18. Selling, General and Administrative Expenses
Selling, general and administrative expenses are comprised of the following items:
Three Months Ended | ||||||
\u00a0\u00a0\u00a0\u00a0 | 2024 | \u00a0\u00a0\u00a0\u00a0 | 2023 | |||
Salaries and benefits | $ | 3,512,736 | $ | 3,797,410 | ||
Professional fees | \u00a0 | 1,427,096 | \u00a0 | 890,167 | ||
Insurance expenses | \u00a0 | 569,185 | \u00a0 | 635,439 | ||
Marketing | 222,014 | 225,113 | ||||
Other expenses | \u00a0 | 1,320,582 | \u00a0 | 1,608,706 | ||
Total | $ | 7,051,613 | $ | 7,156,835 |
"}]},{"name":"rpt:f-656","factDimensions":{"xbrl:concept":"gdnsf:GeneralAndAdministrativeExpensesTableTextBlock","xbrl:period":"2024-01-01T00:00:00/2024-04-01T00:00:00","xbrl:entity":"cik:0001771706"},"factValues":[{"value":"
Three Months Ended | ||||||
\u00a0\u00a0\u00a0\u00a0 | 2024 | \u00a0\u00a0\u00a0\u00a0 | 2023 | |||
Salaries and benefits | $ | 3,512,736 | $ | 3,797,410 | ||
Professional fees | \u00a0 | 1,427,096 | \u00a0 | 890,167 | ||
Insurance expenses | \u00a0 | 569,185 | \u00a0 | 635,439 | ||
Marketing | 222,014 | 225,113 | ||||
Other expenses | \u00a0 | 1,320,582 | \u00a0 | 1,608,706 | ||
Total | $ | 7,051,613 | $ | 7,156,835 |
"}]},{"name":"rpt:f-657","factDimensions":{"xbrl:concept":"us-gaap:LaborAndRelatedExpense","xbrl:period":"2024-01-01T00:00:00/2024-04-01T00:00:00","xbrl:entity":"cik:0001771706","xbrl:unit":"iso4217:USD"},"factValues":[{"value":"3512736","decimals":0}]},{"name":"rpt:f-658","factDimensions":{"xbrl:concept":"us-gaap:LaborAndRelatedExpense","xbrl:period":"2023-01-01T00:00:00/2023-04-01T00:00:00","xbrl:entity":"cik:0001771706","xbrl:unit":"iso4217:USD"},"factValues":[{"value":"3797410","decimals":0}]},{"name":"rpt:f-659","factDimensions":{"xbrl:concept":"us-gaap:ProfessionalFees","xbrl:period":"2024-01-01T00:00:00/2024-04-01T00:00:00","xbrl:entity":"cik:0001771706","xbrl:unit":"iso4217:USD"},"factValues":[{"value":"1427096","decimals":0}]},{"name":"rpt:f-660","factDimensions":{"xbrl:concept":"us-gaap:ProfessionalFees","xbrl:period":"2023-01-01T00:00:00/2023-04-01T00:00:00","xbrl:entity":"cik:0001771706","xbrl:unit":"iso4217:USD"},"factValues":[{"value":"890167","decimals":0}]},{"name":"rpt:f-661","factDimensions":{"xbrl:concept":"us-gaap:GeneralInsuranceExpense","xbrl:period":"2024-01-01T00:00:00/2024-04-01T00:00:00","xbrl:entity":"cik:0001771706","xbrl:unit":"iso4217:USD"},"factValues":[{"value":"569185","decimals":0}]},{"name":"rpt:f-662","factDimensions":{"xbrl:concept":"us-gaap:GeneralInsuranceExpense","xbrl:period":"2023-01-01T00:00:00/2023-04-01T00:00:00","xbrl:entity":"cik:0001771706","xbrl:unit":"iso4217:USD"},"factValues":[{"value":"635439","decimals":0}]},{"name":"rpt:f-663","factDimensions":{"xbrl:concept":"us-gaap:MarketingExpense","xbrl:period":"2024-01-01T00:00:00/2024-04-01T00:00:00","xbrl:entity":"cik:0001771706","xbrl:unit":"iso4217:USD"},"factValues":[{"value":"222014","decimals":0}]},{"name":"rpt:f-664","factDimensions":{"xbrl:concept":"us-gaap:MarketingExpense","xbrl:period":"2023-01-01T00:00:00/2023-04-01T00:00:00","xbrl:entity":"cik:0001771706","xbrl:unit":"iso4217:USD"},"factValues":[{"value":"225113","decimals":0}]},{"name":"rpt:f-665","factDimensions":{"xbrl:concept":"us-gaap:OtherGeneralAndAdministrativeExpense","xbrl:period":"2024-01-01T00:00:00/2024-04-01T00:00:00","xbrl:entity":"cik:0001771706","xbrl:unit":"iso4217:USD"},"factValues":[{"value":"1320582","decimals":0}]},{"name":"rpt:f-666","factDimensions":{"xbrl:concept":"us-gaap:OtherGeneralAndAdministrativeExpense","xbrl:period":"2023-01-01T00:00:00/2023-04-01T00:00:00","xbrl:entity":"cik:0001771706","xbrl:unit":"iso4217:USD"},"factValues":[{"value":"1608706","decimals":0}]},{"name":"rpt:f-667","factDimensions":{"xbrl:concept":"us-gaap:SellingGeneralAndAdministrativeExpense","xbrl:period":"2024-01-01T00:00:00/2024-04-01T00:00:00","xbrl:entity":"cik:0001771706","xbrl:unit":"iso4217:USD"},"factValues":[{"value":"7051613","decimals":0}]},{"name":"rpt:f-668","factDimensions":{"xbrl:concept":"us-gaap:SellingGeneralAndAdministrativeExpense","xbrl:period":"2023-01-01T00:00:00/2023-04-01T00:00:00","xbrl:entity":"cik:0001771706","xbrl:unit":"iso4217:USD"},"factValues":[{"value":"7156835","decimals":0}]},{"name":"rpt:f-669","factDimensions":{"xbrl:concept":"us-gaap:OtherIncomeAndOtherExpenseDisclosureTextBlock","xbrl:period":"2024-01-01T00:00:00/2024-04-01T00:00:00","xbrl:entity":"cik:0001771706"},"factValues":[{"value":"
19. Other Income (Expense)
On May 25, 2023, the Company and Grown Rogue International, Inc. (\u201cGrown Rogue\u201d) entered into a strategic agreement whereby Grown Rogue will support Goodness Growth in the optimization of its cannabis flower products. As part of this strategic agreement Grown Rogue granted the Company\u00a08,500,000\u00a0warrants to purchase subordinate voting shares of Grown Rogue on October 5, 2023. These warrants were valued at $3,265,231 on March 31, 2024 using a stock price of $0.45, an exercise price of $0.17, an expected life of\u00a04.52\u00a0years, an annual risk free rate of\u00a04.21%, and volatility of\u00a0100%. The change in fair value relative to December 31, 2023 of $1,327,879 was recorded as other income in the unaudited condensed consolidated statement of loss and comprehensive loss for the three months ended March 31, 2024.
"}]},{"name":"rpt:f-670","factDimensions":{"xbrl:concept":"gdnsf:WarrantsIssuableUnderAgreement","xbrl:period":"2023-05-25T00:00:00/2023-05-26T00:00:00","xbrl:entity":"cik:0001771706","xbrl:unit":"xbrla:shares","dei:LegalEntityAxis":"gdnsf:GrownRogueInternationalInc.Member"},"factValues":[{"value":"8500000"}]},{"name":"rpt:f-671","factDimensions":{"xbrl:concept":"us-gaap:NontradeReceivablesCurrent","xbrl:period":"2024-04-01T00:00:00","xbrl:entity":"cik:0001771706","xbrl:unit":"iso4217:USD"},"factValues":[{"value":"3265231","decimals":0}]},{"name":"rpt:f-672","factDimensions":{"xbrl:concept":"us-gaap:WarrantsAndRightsOutstandingMeasurementInput","xbrl:period":"2024-04-01T00:00:00","xbrl:entity":"cik:0001771706","xbrl:unit":"iso4217:USD/xbrla:shares","us-gaap:MeasurementInputTypeAxis":"us-gaap:MeasurementInputSharePriceMember"},"factValues":[{"value":"0.45","decimals":2}]},{"name":"rpt:f-673","factDimensions":{"xbrl:concept":"us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1","xbrl:period":"2024-04-01T00:00:00","xbrl:entity":"cik:0001771706","xbrl:unit":"iso4217:USD/xbrla:shares"},"factValues":[{"value":"0.17","decimals":2}]},{"name":"rpt:f-674","factDimensions":{"xbrl:concept":"us-gaap:WarrantsAndRightsOutstandingMeasurementInput","xbrl:period":"2024-04-01T00:00:00","xbrl:entity":"cik:0001771706","xbrl:unit":"gdnsf:Y","us-gaap:MeasurementInputTypeAxis":"us-gaap:MeasurementInputExpectedTermMember"},"factValues":[{"value":"4.52","decimals":2}]},{"name":"rpt:f-675","factDimensions":{"xbrl:concept":"us-gaap:WarrantsAndRightsOutstandingMeasurementInput","xbrl:period":"2024-04-01T00:00:00","xbrl:entity":"cik:0001771706","us-gaap:MeasurementInputTypeAxis":"us-gaap:MeasurementInputRiskFreeInterestRateMember"},"factValues":[{"value":"4.21","decimals":2}]},{"name":"rpt:f-676","factDimensions":{"xbrl:concept":"us-gaap:WarrantsAndRightsOutstandingMeasurementInput","xbrl:period":"2024-04-01T00:00:00","xbrl:entity":"cik:0001771706","us-gaap:MeasurementInputTypeAxis":"us-gaap:MeasurementInputOptionVolatilityMember"},"factValues":[{"value":"100","decimals":0}]},{"name":"rpt:f-677","factDimensions":{"xbrl:concept":"gdnsf:WarrantsValueRecognizedAsOtherIncome","xbrl:period":"2024-01-01T00:00:00/2024-04-01T00:00:00","xbrl:entity":"cik:0001771706","xbrl:unit":"iso4217:USD"},"factValues":[{"value":"1327879","decimals":0}]},{"name":"rpt:f-678","factDimensions":{"xbrl:concept":"us-gaap:CashFlowSupplementalDisclosuresTextBlock","xbrl:period":"2024-01-01T00:00:00/2024-04-01T00:00:00","xbrl:entity":"cik:0001771706"},"factValues":[{"value":"
20. Supplemental Cash Flow Information(1)
\u00a0\u00a0\u00a0\u00a0 | March\u00a031,\u00a0 | March\u00a031,\u00a0 | ||||
\u00a0\u00a0\u00a0\u00a0 | 2024 | \u00a0\u00a0\u00a0\u00a0 | 2023 | |||
Cash paid for interest | $ | 6,799,193 | $ | 5,731,120 | ||
Cash paid for income taxes | \u00a0 | \u2014 | \u00a0 | \u2014 | ||
Change in construction accrued expenses | \u00a0 | (121,433) | \u00a0 | \u2014 | ||
Warrants issued in connection with financing activities | \u00a0 | \u2014 | \u00a0 | \u2014 |
| (1) | For supplemental cash flow information related to leases, refer to Note 9. |
\u00a0\u00a0\u00a0\u00a0 | March\u00a031,\u00a0 | March\u00a031,\u00a0 | ||||
\u00a0\u00a0\u00a0\u00a0 | 2024 | \u00a0\u00a0\u00a0\u00a0 | 2023 | |||
Cash paid for interest | $ | 6,799,193 | $ | 5,731,120 | ||
Cash paid for income taxes | \u00a0 | \u2014 | \u00a0 | \u2014 | ||
Change in construction accrued expenses | \u00a0 | (121,433) | \u00a0 | \u2014 | ||
Warrants issued in connection with financing activities | \u00a0 | \u2014 | \u00a0 | \u2014 |
| (1) | For supplemental cash flow information related to leases, refer to Note 9. |
21. Financial Instruments
Credit risk
Credit risk is the risk of loss associated with counterparty\u2019s inability to fulfill its payment obligations. The Company\u2019s credit risk is primarily attributable to cash, accounts receivable, and notes receivable. A small portion of cash is held on hand, from which management believes the risk of loss is remote. Receivables relate primarily to wholesale sales. The Company does not have significant credit risk with respect to customers. The Company\u2019s maximum credit risk exposure is equivalent to the carrying value of these instruments. The Company has been granted licenses pursuant to the laws of the states of Maryland, Minnesota, and New York with respect to cultivating, processing, and/or distributing marijuana. Presently, this industry is illegal under United States federal law. The Company has adhered, and intends to continue to adhere, strictly to the applicable state statutes in its operations.
Liquidity risk
The Company\u2019s approach to managing liquidity risk is to ensure that it will have sufficient liquidity to meet liabilities when due. As of March 31, 2024, the Company\u2019s financial liabilities consist of accounts payable, accrued liabilities, debt,
and convertible debt. The Company manages liquidity risk by reviewing its capital requirements on an ongoing basis. Historically, the Company\u2019s main source of funding has been additional funding from investors and debt issuances. The Company\u2019s access to financing is always uncertain. There can be no assurance of continued access to significant equity or debt financing.
Legal Risk
Goodness Growth operates in the United States. The U.S. federal government regulates drugs through the Controlled Substances Act (21 U.S.C. \u00a7 811), which places controlled substances, including cannabis, in a schedule. Cannabis is classified as a Schedule I drug. Under U.S. federal law, a Schedule I drug or substance has a high potential for abuse, no accepted medical use in the U.S., and a lack of accepted safety for the use of the drug under medical supervision. The U.S. Food and Drug Administration has not approved marijuana as a safe and effective drug for any indication. In the U.S. marijuana is largely regulated at the state level. State laws regulating cannabis are in direct conflict with the federal Controlled Substances Act, which makes cannabis use and possession federally illegal.
Foreign currency risk
Foreign currency risk is the risk that the fair value or future cash flows of a financial instrument will fluctuate because of changes in foreign currency rates. Given the Company\u2019s financial transactions are rarely denominated in a foreign currency, there is minimal foreign currency risk exposure.
Interest rate risk
Interest rate risk is the risk that the fair value of future cash flows of a financial instrument will fluctuate because of changes in market interest rates. The Company currently carries variable interest-bearing debt subject to fluctuations in the United States Prime rate. A change of 100 basis points in interest rates during the three months ended March 31, 2024, would have resulted in a corresponding change in the statement of loss and comprehensive loss of $138,570.
"}]},{"name":"rpt:f-684","factDimensions":{"xbrl:concept":"gdnsf:InterestRateRiskEffectOnNetIncomeOfOneHundredBasisPointChangeInPrimeRate","xbrl:period":"2024-01-01T00:00:00/2024-04-01T00:00:00","xbrl:entity":"cik:0001771706","xbrl:unit":"iso4217:USD"},"factValues":[{"value":"138570","decimals":0}]},{"name":"rpt:f-685","factDimensions":{"xbrl:concept":"us-gaap:RelatedPartyTransactionsDisclosureTextBlock","xbrl:period":"2024-01-01T00:00:00/2024-04-01T00:00:00","xbrl:entity":"cik:0001771706"},"factValues":[{"value":"
22. Related Party Transactions
As of March 31, 2024, and December 31, 2023, there were $0 and $121,846 due to related parties, respectively.
"}]},{"name":"rpt:f-686","factDimensions":{"xbrl:concept":"us-gaap:OtherLiabilities","xbrl:period":"2024-04-01T00:00:00","xbrl:entity":"cik:0001771706","xbrl:unit":"iso4217:USD"},"factValues":[{"value":"0","decimals":0}]},{"name":"rpt:f-687","factDimensions":{"xbrl:concept":"us-gaap:OtherLiabilities","xbrl:period":"2024-01-01T00:00:00","xbrl:entity":"cik:0001771706","xbrl:unit":"iso4217:USD"},"factValues":[{"value":"121846","decimals":0}]},{"name":"rpt:f-688","factDimensions":{"xbrl:concept":"us-gaap:SubsequentEventsTextBlock","xbrl:period":"2024-01-01T00:00:00/2024-04-01T00:00:00","xbrl:entity":"cik:0001771706"},"factValues":[{"value":"23. Subsequent Events
On April 1, 2024, the Company executed a eighth amendment to its lease with its landlord on its cannabis cultivation and manufacturing facilities located in Johnstown, New York. As part of the eighth amendment to the lease in Johnstown, the Company extended its option to terminate the lease. Written notice of termination now needs to be provided by June 15, 2024. Additionally, the Company has a purchase option to buy the premises for\u00a0$81,000,000. The purchase option extends through March 27, 2026, and the purchase price increases\u00a03%\u00a0every six months.
On April 1, 2024, ACE Ventures, LLC (\u201cAce\u201d), a minority-owned business partnership in the State of New York, and the Company executed a binding term sheet whereby Ace plans to acquire the Company\u2019s subsidiary, Vireo Health of New York (\u201cVireoNY\u201d), pending the satisfaction of closing conditions, including secured capital commitments and regulatory approval. Terms of the transaction include a purchase price between\u00a0$3.0\u00a0and\u00a0$5.0\u00a0million for Vireo Health of New York\u2019s licenses, inventory and assets, as well as either Ace\u2019s assumption of the lease agreement with Innovative Industrial Properties (\u201cIIP\u201d) for the Johnstown, NY cannabis cultivation and manufacturing campus or Ace\u2019s acquisition of this campus. Ace has agreed to take financial responsibility for VireoNY\u2019s operations, including its operating losses, beginning on April 1, 2024. These activities are expected to be supported initially by a\u00a0$2.5\u00a0million unsecured loan from the Company to VireoNY.
On May 1, 2024, The Company announced that Josh Rosen, who has served as Interim CEO since February of 2023, has been appointed as Chief Executive Officer, effective immediately. Mr. Rosen, retains his Interim Chief Financial Officer title.
On May 1, 2024, The Company announced that it is in ongoing discussions with its senior secured lender, Chicago Atlantic Admin, LLC, an affiliate of Green Ivy Capital, to finalize a longer-term extension of its credit agreement. While this process remains ongoing, the parties have agreed to a short-term extension of the maturity date on their term loan until June 14, 2024, matching all other terms of the existing agreement.
On May 2, 2024, the Company announced that it has filed an application with the Supreme Court of British Columbia for summary determination in its ongoing litigation with Verano Holdings, Inc. (\u201cVerano\u201d) related to Verano\u2019s wrongful termination of the share exchange agreement (the \u201cArrangement Agreement\u201d) between the parties pursuant to which Verano agreed to acquire all of the outstanding capital stock of the Company in a transaction announced on February 1, 2022. The Company is seeking substantial damages, specifically US $869.0 million, as well as other costs and legal fees, based on Verano\u2019s breach of contract and of its duty of good faith and honest performance. While the Company\u2019s filing of its application for summary determination reflects its belief that Verano\u2019s defense against its claims of unlawful conduct is without merit, the Company can make no assurances regarding the expected timeframe to resolve this litigation, or its ability to recover damages from Verano.
"}]},{"name":"rpt:f-689","factDimensions":{"xbrl:concept":"gdnsf:LeaseOptionToRepurchasePropertyInitialPurchasePrice","xbrl:period":"2024-04-02T00:00:00","xbrl:entity":"cik:0001771706","xbrl:unit":"iso4217:USD","us-gaap:SubsequentEventTypeAxis":"us-gaap:SubsequentEventMember","us-gaap:TypeOfArrangementAxis":"gdnsf:EighthAmendmentMember"},"factValues":[{"value":"81000000","decimals":0}]},{"name":"rpt:f-690","factDimensions":{"xbrl:concept":"gdnsf:LeaseInitialPurchasePriceAnnualIncrementalPercentage","xbrl:period":"2024-04-02T00:00:00","xbrl:entity":"cik:0001771706","us-gaap:SubsequentEventTypeAxis":"us-gaap:SubsequentEventMember","us-gaap:TypeOfArrangementAxis":"gdnsf:EighthAmendmentMember"},"factValues":[{"value":"0.03","decimals":2}]},{"name":"rpt:f-691","factDimensions":{"xbrl:concept":"us-gaap:BusinessCombinationPriceOfAcquisitionExpected","xbrl:period":"2024-04-01T00:00:00/2024-04-02T00:00:00","xbrl:entity":"cik:0001771706","xbrl:unit":"iso4217:USD","srt:CounterpartyNameAxis":"gdnsf:AceVenturesLlcMember","srt:RangeAxis":"srt:MinimumMember","us-gaap:SubsequentEventTypeAxis":"us-gaap:SubsequentEventMember"},"factValues":[{"value":"3000000.0","decimals":-5}]},{"name":"rpt:f-692","factDimensions":{"xbrl:concept":"us-gaap:BusinessCombinationPriceOfAcquisitionExpected","xbrl:period":"2024-04-01T00:00:00/2024-04-02T00:00:00","xbrl:entity":"cik:0001771706","xbrl:unit":"iso4217:USD","srt:CounterpartyNameAxis":"gdnsf:AceVenturesLlcMember","srt:RangeAxis":"srt:MaximumMember","us-gaap:SubsequentEventTypeAxis":"us-gaap:SubsequentEventMember"},"factValues":[{"value":"5000000.0","decimals":-5}]},{"name":"rpt:f-693","factDimensions":{"xbrl:concept":"us-gaap:UnsecuredDebt","xbrl:period":"2024-04-02T00:00:00","xbrl:entity":"cik:0001771706","xbrl:unit":"iso4217:USD","srt:CounterpartyNameAxis":"gdnsf:AceVenturesLlcMember","us-gaap:SubsequentEventTypeAxis":"us-gaap:SubsequentEventMember"},"factValues":[{"value":"2500000","decimals":-5}]},{"name":"rpt:f-694","factDimensions":{"xbrl:concept":"us-gaap:LossContingencyDamagesSoughtValue","xbrl:period":"2024-05-02T00:00:00/2024-05-03T00:00:00","xbrl:entity":"cik:0001771706","xbrl:unit":"iso4217:USD","srt:CounterpartyNameAxis":"gdnsf:VeranoMember"},"factValues":[{"value":"869000000.0","decimals":-5}]}]}}